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ABSTRACT 
 
PREPARATION AND EVALUATION OF CHITOSAN 
MICROSPHERES FOR ERADICATION OF HELICOBACTER PYLORI 
 
The main focus of this dissertation is to develop chitosan based microspheres 
loaded with antibiotic and essential oil to eradicate Helicobacter pylori by maintaining 
the constant drug level and prolonged gastric retention. The primary objective was to 
show that novel essential oil loaded microspheres are promising in the treatment of H. 
pylori infection as an alternative to conventional antibiotic therapy. In this context, 
firstly, the minimum inhibitory concentration of clarithromycin and five essential oils 
namely lemongrass oil, thyme oil, clove leaf oil, lemon oil and cinnamon bark oil on H. 
pylori was investigated. Among five essential oils, cinnamon bark oil showed the 
strongest anti-H. pylori activity. 
After choosing the most effective essential oil on H. pylori, we focused on the 
preparation of clarithromycin and cinnamon bark oil loaded microspheres by spray 
drying technique. Spray drying conditions were optimized by reponse surface 
methodology. Genipin, a natural crosslinker, was used as a crosslinking agent to achieve 
controlled drug release.  
Finally, it was aimed to investigate the clarithromycin and essential oil release in 
buffer solution and their antibacterial activity on H. pylori when released from 
microspheres.  Higuchi equation well described the release characteristics. Drug release 
from microspheres was diffusion controlled. Cinnamon bark oil and clarithromycin 
released from the microspheres inhibited the growth of H. pylori resulting that the 
antibacterial activity of cinnamon bark oil and clarithromycin was maintained during 
the microsphere manufacturing. In conclusion, clarithromycin and cinnamon bark oil 
loaded chitosan microspheres have a great potential to be used as a control release 
system in treatment of H. pylori infection.  
 v 
ÖZET 
 
HELICOBACTER PYLORI‟NĠN ERADĠKASYONU ĠÇĠN KĠTOSAN 
MĠKROKÜRELERĠN HAZIRLANMASI VE DEĞERLENDĠRĠLMESĠ 
 
Bu tezin odak noktası Helicobacter pylori’nin eradikasyonu için sabit ilaç 
seviyesini sağlayan ve midede tutulma süresinin uzatan antibiyotik ve uçucu yağ yüklü 
kitosan bazlı mikroküreleri geliĢtirmektir. Antibakteriyel ajanların mukoyapıĢkan ilaç 
taĢıyıcı sistemlerden kontrollü salımı, önemlidir. Tezin ana amacı uçucu yağ yüklü 
mikrokürelerin H. pylori infeksiyonunun tedavisinde geleneksel antibiyotik tedavilerine 
alternatif olarak kullanılabilecek, umut vaad eden, orijinal bir sistem olduğunu 
göstermektir. Bu kapsamda ilk olarak klaritromisin ile limonotu, kekik, karanfil, limon 
ve tarçın uçucu yağlarının H. pylori üzerine minimum inhibisyon konsantrasyonları 
(MĠK) araĢtırıldı. BeĢ uçucu yağ arasında en güçlü anti-H. pylori aktivitesini tarçın yağı 
gösterdi. 
H. pylori üzerine en etkili uçucu yağ seçildikten sonra klaritromisin ve tarçın 
yağı yüklü mikrokürelerin püskürtmeli kurutma tekniğiyle eldesine odaklanıldı. 
Püskürtmeli kurutma koĢulları tepki yüzey yöntemiyle optimize edildi. Kontrollü ilaç 
salımını sağlamak için doğal bir çapraz bağlama ajanı olan genipin kullanıldı.  
Son olarak klaritromisin ve tarçın yağının mikrokürelerden tampon çözeltiye 
salımının ve mikrokürelerden ortama salınan klaritromisin ve tarçın yağının H. pylori 
üzerine antibakteriyel aktivitelerinin araĢtırılması hedeflendi. Salım karakteristiğini 
Higuchi denklemi iyi açıkladı. Mikrokürelerden ilaç difüzyon kontrollü salım olarak 
belirlendi. Mikrokürelerden salınan klaritromisin ve tarçın yağının H. pylori üremesini 
inhibe etmesi klaritromisin ve tarçın yağının antibakteriyel aktivitelerinin mikroküre 
üretimi sırasında korunduğunu gösterdi. Sonuç olarak klaritromisin ve tarçın yağı yüklü 
mikrokürelerin H. pylori infeksiyonunun tedavisinde kullanılabilecek potansiyel bir 
kontrollü salım sistemi olduğu belirlendi. 
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CHAPTER 1 
 
INTRODUCTION 
 
Helicobacter pylori (H. pylori) is one of the most common patogens in the world 
and it may be very important risk factor on human life unless its infection is treated 
immediately. Although the microorganism is susceptible many antimicrobial agents, the 
eradication rate is very low due to poor permeability of the antibiotics across the mucus 
layer, poor stability of the drug in the acidic pH of the gastric fluid, short residence time 
of antibiotic in the stomach and development of resistance to antimicrobial agents. 
Triple therapy consisting of combined use of antibiotics, such as amoxicillin, 
clarithromycin or metronidazole, and a proton pump inhibitor gives better eradication 
rate than the monotherapy, and is now frequently used for clinical treatment of H. pylori 
associated gastroduodenal disease. However, harmful side effects, cost of therapy, and 
the lack of willingness to take many different drug products are the major drawbacks of 
triple therapy (Majithiya and Murthy, 2005; Zheng et al., 2006). For this reason, 
considerable interest has focused recently on the new drug delivery systems that deliver 
the antibiotic locally in the stomach by increasing residence time of antibiotics at 
infected site and biologically active compounds including antioxidants from plants and 
other natural sources as an alternative to antibiotics (Rajinikanth et al., 2008). 
One way to improve the efficacy in eradicating the infection is to develop 
mucoadhesive drug carriers which may prolong the residence time in the 
gastrointestinal tract (GI) because they can adhere to the mucus surface, resulting in an 
effective localized drug concentration (Rajinikanth et al., 2008). Among several 
mucoadhesive polymers, chitosan is gaining attention in the pharmaceutical field for a 
wide range of drug delivery since it is known to be a natural, biocompatible, 
biodegradable and nontoxic. Clarithromycin is a macrolide and widely used in a 
standard eradication treatment of H. Pylori infection combined with a second antibiotic 
and an acid-suppressing agent (Rajinikanth et al., 2008). It has the highest eradication 
rate of H. pylori in monotherapy in vivo and hence was selected as a model drug in this 
study. 
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Another way to increase eradication rate is to use biologically active compounds 
such as essential oils as an alternative to antibiotics or as food additives to complement 
present therapies.  Although essential oils have a broad spectrum of activity, not all of 
them are able to kill all bacteria. There has been an increased interest in looking at 
antimicrobial properties of extracts from aromatic plants particularly essential oils 
(Bergonzelli et al., 2003; Prabuseenivasan et al., 2006). Since there are not any 
assignments about the resistance of H. pylori to essential oils, the use of essential oils to 
eradicate the antibiotic-resistant strain of H. pylori and for patients having antibiotic 
allergy is promising (Shaik et al., 2005). There are also limited number of studies on the 
production of essential oil loaded microspheres and their controlled release profiles. 
Although, there is a study about citronella oil encapsulation by chitosan using o/w 
emulsion method, there is not any study on the H. pylori eradication with essential oil 
loaded microspheres (Hsieh et al., 2006). 
The main purpose of this dissertation was to develop chitosan based 
microspheres loaded with antibiotic and essential oil to eradicate H. pylori. This 
stomach-specific delivery system would increase the gastric residence time and allow 
more of the antibiotic to penetrate through the gastric mucus layer and act locally at the 
infectious site. First of all, the minimum inhibitory concentration (MIC) of 
clarithromycin and five essential oils namely lemongrass oil, thyme oil, clove leaf oil, 
lemon oil and cinnamon bark oil on H. pylori was determined by agar dilution method 
(Clinical and Laboratory Standards Institute, 2007) that shows the potential use of 
essential oils for the eradication of H. pylori. The composition of essential oils was 
determined by GC-MS. Trolox equivalent antioxidant capacity of essential oils was 
calculated from the percentage inhibition curves by using ABTS. Since the cinnamon 
bark oil exhibited highest anti-H. pylori activity, clarithromycin and cinnamon bark oil 
loaded chitosan microspheres were obtained by spray drying. The significance of some 
parameters (inlet air temperature, drug concentration and feed flow rate) on spray 
drying efficiency and properties of clarithromycin and cinnamon bark oil loaded 
microspheres in terms of the water activity and morphology, and also the optimum 
conditions were determined by Central Composite Design (CCD) and Response Surface 
Methodology (RSM). The surface morphology, thermal properties, swelling and 
degradation properties and the structures of resultant microspheres produced according 
to the optimum conditions were investigated by SEM, DSC and TGA, phase contrast 
microscopy and 
1
H-NMR spectroscopy, respectively. To achieve controlled release, 
 3 
genipin crosslinked microspheres were manufactured by changing the genipin 
concentration and crosslinking time. The stability of clarithromycin in different pH 
solutions was examined. Clarithromycin and cinnamon bark oil release from the 
microspheres were carried out in phosphate buffer solution and model equations were 
used to explain the release mechanism. Finally, the antibacterial activity of 
clarithromycin and cinnamon bark oil released from microspheres were tested on H. 
pylori. 
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CHAPTER 2 
 
HELICOBACTER PYLORI 
 
Helicobacter pylori (H. pylori) is a spiral-shaped, microaerophilic, gram-
negative bacteria which colonize gastric mucosa. H. pylori is related to a number of 
upper gastrointestinal diseases, such as chronic gastritis, duodenal and gastric ulcer, 
gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma 
and has been classified as a class 1 carcinogen by “International Agency for Cancer 
Research (IACR)‟‟ in 1994 (Graham and Graham, 2002). Considering gastroduodenal 
diseases related to H. pylori infection, this bacterium has the important role in terms of 
public health. H. pylori is localized in gastric mucus-secreting cells found in or under a 
layer of mucus and target the gastric epithelial cells (Wallis-Crespo and Crespo, 2004).  
H. pylori has been found in the stomachs of humans in all parts of the world. In 
developing countries, 70 to 90% of the population carries H. pylori; almost all of these 
acquire the infection before the age of 10 years. In developed countries, the prevalence 
of infection is lower, ranging from 25 to 50% (Dunn et al., 1997). 
Although H. pylori is sensitive to a wide range of antibiotics in vitro, they all fail 
as monotherapy in vivo. In infected patients, the most effective single drug is 
clarithromycin, which leads to an approximate eradication rate of 40% when given 
twice daily for 10 to 14 days. Dual therapies, combining twice-daily-dosed PPI with, in 
particular, amoxicillin, are stil in use in some countries, but dual therapies have mostly 
been replaced by triple therapies. Tetracycline, amoxicillin, imidazoles (predominantly 
metronidazole and tinidazole), and a few selected macrolides (in particular 
clarithromycin, sometimes azithromycin) are probably the drugs most widely used for 
H. pylori eradication therapy. The use of these drugs has resulted in effective therapies 
against H. pylori, with consistent eradication rates over 80%. Various treatment 
durations, doses, and drug combinations have been studied, but none have consistently 
reached eradication levels in excess of 90 to 95%. Failures are in particular related to 
insufficient therapy adherence, often because of side effects, and to the presence of 
antimicrobial resistance. Such resistance is common in patients who have had previous 
antibiotic treatment, including failed eradication therapies (Kusters et al., 2006). The 
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reported failures of antibiotic therapy could be due to poor permeability of the 
antibiotics across the mucus layer or due to poor stability of the drug in the acidic pH of 
the stomach. Moreover, conventional tablets or capsules do not remain in the stomach 
long. Therefore, antibiotics might not have enough time to diffuse into the mucosa 
layer, and the antibiotic concentrations in the gastric mucus can not reach minimum 
inhibitory concentrations (Majithiya and Murthy, 2005; Zheng et al., 2006).  
 
2.1. History 
 
H. pylori was first identified in 1983 by Robin Warren (pathologist) and Barry 
Marshall (gastroenterologist) and it has been understood that H. pylori infection is the 
main cause of human gastritis and peptic ulcer. H. pylori infection during childhood 
may lead stomach cancer in old ages. So, H. pylori has been classified by WHO (the 
World Health Organization) as a “class I human carcinogen” in 1994 (Kusters et al., 
2006; Radosz-Komoniewska et al., 2005). In 2005, the Nobel Prize in Physiology or 
Medicine was attributed to B. Marshall and R. Warren who showed the public health 
importance of the discovery of H. pylori and its role in stomach diseases (Megraud and 
Lehours, 2007). 
 
2.2. Morphology 
 
H. pylori is a gram-negative bacterium, measuring 2 to 4 mm in length and 0.5 
to 1 mm in width. Although usually spiral-shaped, the bacterium can appear as a rod, 
while coccoid shapes appear after prolonged in vitro culture or antibiotic treatment. The 
organism has 2 to 6 unipolar, sheathed flagella of approximately 3 mm in length, which 
often carry a distinctive bulb at the end. The flagella confer motility and allow rapid 
movement in viscous solutions such as the mucus layer overlying the gastric epithelial 
cells. In contrast to many other pathogens of the gastrointestinal tract, it lacks fimbrial 
adhesins. H. pylori is urease, catalase, and oxidase positive, characteristics which are 
often used in identification of H. pylori. H. pylori can catabolize glucose, and both 
genomic and biochemical information indicates that other sugars cannot be catabolized 
by H. pylori (Kusters et al., 1997).  
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2.3. H. pylori Infections 
 
Helicobacter pylori colonizes in the stomach of humans and causes of chronic 
gastritis, peptic ulcer disease (PUD), gastric cancer, and mucosa-associated lymphoid 
tissue lymphoma (MALToma). Once established, it may reside in the gastric mucosa for 
years, possibly for the life of the host, because the immunological defense mechanisms 
of the host fail to eliminate it (Rudi et al., 1998). Although most bacteria quickly die in 
stomach acid (pH 2) H. pylori thrive in the stomach. Under acidic conditions, H. pylori 
use a type of enzyme called urease to convert urea, found in low levels in stomach, into 
ammonia and carbondioxide. The resulting ammonia neutralizes stomach acid, making 
the bacteria‟s microenvironment hospitable. H. pylori travel by whipping their tail-like 
flagella. Upon entering the stomach, the bacteria propel themselves through the mucus 
gel that lines and protects the stomach‟s epithelial cells. Under the mucus, the bacteria 
attach to the epithelial cells and continue to use urease to deacidify their 
microenvironment. Without urease, H. pylori can not colonize the stomach (Rudi et al., 
1998, Salyers and Whitt, 2002, Stingl et al., 2008). 
 
2.4. Clarithromycin 
 
In the eradication of H. pylori infections, the macrolides of clarithromycin, 
amoxicilline or nitroimidazole group antibiotic of metronidazole with proton pump 
inhibitor (PPI) were used for 7 and 14 days therapy. Bacterial resistance to 
antimicrobial agents is currently considered as an increasing problem in the treatment of 
infectious diseases in general. Resistance of H. pylori to clarithromycin is regarded as a 
particular dilemma, since this drug is a part of established therapy regimen. Thus, 
macrolide resistance is a frequent cause for failure of H. pylori eradication therapy and 
secondary clarithromycin resistance rates in patients with a history of failed eradication 
attempts frequently exceed 50%. Also in the general population the prevalence of 
macrolide-resistant H. pylori has been increasing over the years, primarily in the 
industrial countries. Primary clarithromycin resistance rates reach up to 10% in Europe 
(Juttner et al., 2004). Among the macrolides, clarithromycin is currently widely used 
because of its low MIC‟s (minimum inhibitory concentration which is able to inhibit the 
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growth of bacteria) against H. pylori and its good pharmacokinetic properties (Megraud, 
1997; Rimbara et al., 2011).  
 
2.4.1. Structure 
 
The macrolides are a group antibiotics whose activity stems from the presence of 
14-16-membered macrocyclic lactone ring to which one or more deoxy sugars, usually 
cladinose and desosamine, may be attached (Figure 2.1) Clarithromycin (6-O-
methylerythromycin) is synthesized by substituting a methoxy group for the C-6 
hydroxyl group of erythromycin. This substitution creates a more acid-stable 
antimicrobial and prevents the degradation of the erythromycin base to the hemiketal 
intermediate. The increased acid stability of clarithromycin results in improved oral 
bioavailability and reduced gastrointestinal intolerance (Dinos et al., 2003). 
 
 
 
Figure 2.1. Chemical structure of clarithromycin  
(Source: Kusters et al., 2006). 
 
2.4.2. Mechanism of Action 
 
It has been well documented that macrolides bind to the large ribosomal subunit 
in the vicinity of the peptidyl transferase center and cause cell growth arrest due to 
inhibition of protein synthesis. The precise mechanism of protein synthesis inhibition by 
macrolides depends on the specific chemical structure of the drug molecule. This affects 
its interaction with the ribosome as well as the mode of the inhibitory action. Four 
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modes of inhibition of protein synthesis have been ascribed to macrolides: 1) Inhibition 
of the progression of the nascent peptide chain during early rounds of translation; 2) 
Promotion of peptidyl tRNA dissociation from the ribosome; 3) Inhibition of peptide 
bond formation; and 4) Interference with 50S subunit assembly. All of these 
mechanisms have some correlation with the location of the macrolide binding site on 
the ribosome (Gaynor and Mankin, 2005). Clarithromycin exerts its antibacterial effect 
by reversibly binding to the peptidil transferase zone in 50S ribosomal subunit of H. 
pylori by hydrogen bonding with the cladinose sugar connected to C3 with α-glicosidic 
bond of clarithromycin (Zuckerman, 2004; Gerrits et al., 2006). 
Clarithromycin is a kind of bacteriostatic antibiotic (Gibreel et al., 2005; 
Mckenna and Evans, 2001). The minimum inhibitory concentration (MIC), the smallest 
concentration of antibiotics which is able to inhibit the growth of bacteria, of 
clarithromycin was reported as 0.03-0.06 µg/mL (Mckenna and Evans, 2001). Safak et 
al. 2009, have determined the MIC50 and MIC90 values as 0.064 µg/mL and 2.0 µg/mL, 
respectively, by agar dilution method (Safak et al., 2009). Among 106 patients H. pylori 
isolates, MIC90 was determined as 1 µg/mL (Kohanteb et al., 2007). Vega et al. 2009, 
have reported the MIC of H. pylori NCTC 11638 standard strain as 0.125 mg/L (Vega 
et al., 2009). The MIC‟s of clarithromycin resistant H. pylori strains having A2143G 
and A2142G mutations have been reported as 0.5-4 µg/mL and 8-32 µg/mL, 
respectively (Taylor, 2000). H. pylori strains associated with A2143G, A2142G and 
A2142C mutations had MIC‟s in a range of 64-128 µg/mL (Gibreel et al., 2005). 
 
2.4.3. Stability 
 
There are several possible explanations for the absence of a truly successful H. 
pylori eradication regimen. These include the drug delivery problems associated with 
directing antibacterial agents to the protective residential microenvironment in the 
gastric mucosa, the presence of „sanctuary sites‟ for H. pylori such as extragastric sites, 
regions of the stomach sites such as gastric pits, and the chemical stability of 
antibacterial agents (Zheng et al., 2006). To inhibit H.pylori, minimum inhibitory 
concentrations of the drug should be available around the adherent mucus layer and 
gastric epithelial cells where H. pylori resides. The maintenance of inhibitory 
concentrations in the gastric milieu after intravenous drug administration depends on the 
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ability of the drug to be transferred to the gastric milieu from the blood circulation and 
the solubility of the drug in the mucus layer around H. pylori. After oral adminstration, 
the drug must be able to diffuse through the gastric mucus in sufficient amounts to 
generate antibacterial activity at sites of H. pylori residence (Erah et al., 1997).  
Although metronidazole is known to be stable between pH 3.9 and 6.6, 
amoxycillin and clarithromycin are unstable at low pH, and the instability of these drugs 
at the normal gastric pH (pH 1–2) may affect their delivery to the sites where H. pylori 
resides in the stomach. The optimum stability of clarithromycin have been found over 
the pH range 5.0–8.0. At pH values below 5.0, the degradation rate increased markedly 
and 90.2% and 41.1% of clarithromycin was calculated to have been lost from the 
aqueous samples at pH 1.0 and pH 2.0, respectively, within the first hour of the 
experiment (Erah et al., 1997). The use of omeprazole, which is a potent proton-pump 
inhibitor which markedly reduces the secretion of acid in the stomach, hence increasing 
gastric pH towards neutrality to raise the pH of the stomach in patients receiving oral 
clarithromycin, has been reported to be necessary for the desired therapeutic effect. 
(Erah et al., 1997). 
Clarithromycin undergoes hepatic metabolism; at least eight metabolites are 
recovered. 14-Hydroxyclarithromycin is the only metabolite shown to be both 
microbiologically active and present in the plasma at high concentrations. 
Approximately 20%-30% of a dose is recovered in the urine as unchanged 
clarithromycin. Another 10%-15% is recovered in the urine as 14-
hydroxyclarithromycin. The mean elimination half-lives of clarithromycin and 14-
hydroxyclarithromycin are 2.7-4.8 hours and 4.1-8.7 hours, respectively (Rodvold and 
Piscitelli, 2003). 
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CHAPTER 3 
 
ESSENTIAL OILS AGAINST HELICOBACTER PYLORI 
 
Essential oils are natural, volatile, complex, multi-component systems composed 
mainly of terpenes in addition to some other non-terpene components. They are used in 
the preservation of foods and as antimicrobial, analgesic, sedative, anti-inflammatory, 
spasmolytic and locally anesthetic remedies (Gupta and Kumar, 2000; Liu et al., 2000) 
Essential oils are liquid, limpid and rarely colored, lipid soluble and soluble in 
organic solvents with a generally lower density than that of water. They are synthesized 
by all plant organs, i.e. buds, flowers, leaves, stems, twigs, seeds, fruits, roots, wood or 
bark, and are stored in secretory cells, cavities, canals, epidermic cells or glandular 
trichomes. According to climate, soil composition, plant organ, age and vegetative cycle 
stage, extraction product can vary in quality, quantity and in composition. At present, 
approximately 3000 essential oils are known, 300 of which are commercially important 
especially for the pharmaceutical, agronomic, food, sanitary, cosmetic and perfume 
industries. Essential oils having antimicrobial activity are listed in Table 3.1.  
 
Table 3.1. Essential oils having antimicrobial activity 
 
Essential oils 
Bergamot oil (Citrus Bergamia) Juniper oil, (Juniperus communis) 
Black pepper oil, (Piper nigrum) Lavender oil, (Lavandula officinalis) 
Cajeput oil, (Melaleuca cajuputi) Lemon oil, (Citrus limonum) 
Camphor oil, (Cinnamomum camphora) Lemongrass oil, (Cymbopogan citratus) 
Cardamom oil, (Eletteria cardamomum) Lime oil, (Citrus aurantiflora) 
Chamomile oil, (Matricaria chamomilla) Mandarin (red) oil, (Citrus reticulate) 
Citronella oil, (Cymopogan nardus) Melissa oil, (Melissa officinalis) 
Cypress, (Cupessus sempervirens) Myrrh oil, (Commiphora myrrha) 
Eucalyptus oil (Eucalyptus globules) Orange oil (sweet), (Citrus sinensis) 
Fennel oil, (Foeniculum vulgare) Oregano oil, (Origanum vulgare) 
Frankincense oil, (Boswellia frereana) Peppermint oil, (Mentha piperita) 
Geranium oil, (Geranium pretense) Pine oil, (Pinus nigra) 
Helichrysum oil, (Helichrysum italicum) Tangerine oil, (Citrus reticulate) 
Jasmine oil, (Jasminum grandiflorum) Tea (Melaleuca alternifolia) 
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Essential oils or some of their components are used in perfumes and make-up 
products, in sanitary products, in dentistry, in agriculture, as food preservers and 
additives, and as natural remedies. Major components of essential oils that exhibit 
antibacterial properties are tabulated in Table 3.2. Moreover, some essential oils appear 
to exhibit particular medicinal properties that have been claimed to cure one or another 
organ disfunction or systemic disorder (Bakkali et al., 2007). 
Several techniques can be used to extract essential oils from different parts of the 
aromatic plant, including water or steam distillation, solvent extraction, expression 
under pressure, supercritical fluid and subcritical water extractions (Edris, 2007). 
Essential oils, as natural sources of phenolic components, attract investigators to 
evaluate their activity as antioxidants or free radical scavengers. The essential oils of 
basil, cinnamon, clove, nutmeg, oregano and thyme have been proven radical-
scavenging and antioxidant properties in the DPPH radical assay at room temperature 
(Tomaino et al., 2005). The antioxidant activity of essential oils cannot be attributed 
only to the presence of phenolic constituents; monoterpene alcohols, ketones, 
aldehydes, hydrocarbons and ethers also contribute to the free radical scavenging 
activity of some essential oils. It is clear that essential oils may be considered as 
potential natural antioxidants and could perhaps be formulated as a part of daily 
supplements or additives to prevent oxidative stress that contributes too many 
degenerative diseases. The suppression effects of essential oils on glioma, colon cancer, 
gastric cancer, human liver tumor, pulmonary tumors, breast cancer, leukemia and 
others have been tested on human cancer cells (Edris, 2007). 
The phenolic compounds also show inhibitory effects to many microorganisms. 
The mechanism by which phenolic compounds affect the growth of H. pylori is 
unknown, but different theories have been proposed, for example, inhibition of the 
urease activity, adhesion to human gastric mucus, disintegration of the outer membrane, 
and inhibition of VacA citotoxin activity which causes the development of 
inflammation and ulceration in patients (Romero et al., 2007). Abascal and Yarnell 
indicated that plant based materials having antimicrobial properties may be used as an 
alternative or combined to the antibiotics yielding lowered antimicrobial resistance 
(Abascal and Yarnell, 2002). 
Essential oils showing inhibitory effect on H. pylori were summarized in Table 
3.3. Among these essential oils, lemongrass and lemon verbana essential oils have 
shown the inhibition both in vitro and in vivo conditions (Ohno et al., 2003). The 
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activities of 60 essential oils against H. pylori were evaluated and the results showed 
that 30 oils were able to affect the growth in vitro, and 15 showed strong activity. 
Among the individual constituents of these oils, carvacrol, isoeugenol, nerol, citral and 
sabinene exhibited the strongest anti-H. pylori effects (Bergonzelli et al., 2003). 
Moreover, there are many essential oils having antimicrobial activity for different kind 
of microorganisms that are tabulated in Table 3.2. Therefore, these essential oils may be 
potential H. pylori inhibitors.  
 
Table 3.2. Major components of essential oils that exhibit antibacterial properties 
 
 
 
Bergonzelli et al. screened 60 essential oils for their anti-H. pylori properties. It 
was identified that 30 essential oils were able to inhibit H. pylori growth in vitro and 15 
of them had great bactericidal activities. Among these essential oils, carrot seed, 
cinnamon bark, manuka and savory oils displayed the strongest bactericidal potential 
against H. pylori. Cinnamon oil was used as a positive control since the oil and its 
extracts had already been showed as active against H. pylori in previous studies. 
Moreover, it was reported to be better determining the antibacterial activities of 
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essential oil components rather than that of oil in case the composition may change in 
different climates and regions (Bergonzelli et al., 2003). Ohno et al. stated that thirteen 
essential oils used in their study completely inhibited the growth of H. pylori in vitro at 
a concentration of 0.1% (v/v). Cymbopogon citratus (lemongrass) and Lippia citriodora 
(lemon verbena) were bactericidal against H. pylori at 0.01% at pH 4.0 and 5.0. In vivo 
studies demonstrated the density of H. pylori in the stomach of mice treated with 
lemongrass was significantly reduced compared with untreated mice. Regarding these 
results, the use of essential oils has been asserted as new and safe antimicrobial to 
overcome the resistance problem in eradication of H. pylori (Ohno et al., 2003). On the 
contrary to increase in antibiotic resistance, there has been no indication of resistance to 
plants and plant based drugs. Shikov et al. determined the MIC of Chamomilla recutita 
oil as 125 mg/ml. At this concentration urease enzyme production has stopped and the 
morphological property of H. pylori has changed. Thus, it was stated that the 
Chamomilla recutita oil may be used in the treatment of stomach ulcers and duodenal 
intestinal diseases and to eradicate the antibiotic resistant strains of H. pylori (Shikov et 
al., 2008). 
 
Table 3.3. Essential oils effective in H. Pylori eradication 
 
Essential Oils Results  
in vitro/in vivo 
Reference 
Lemongrass 
lemon verbena 
+/+ (Ohno et al. 2003) 
 
Carrot seed, Cinnamon bark, Clove 
Caraway, Eucalyptus, Pink grapefruit, 
White grapefruit, Lemongrass, Manuka, 
Oregano (vulgaris) Sage, Savory, 
Tarragon, Thyme (red), Thyme (vulgaris), 
Vervein 
+/- (Bergonzelli et al. 
2003) 
 
 
Chamomilla recutita +/n.s (Shikov et al. 2008) 
Dittrichia viscosa +/n.s (Miguel et al. 2008) 
Garlic Oil, Garlic Powder +/n.s (O‟gara et al. 2000) 
Origanum, cassia, cumin, 
lavender oils, myrtle and bay leaf 
pumpkin seed and sage, olive oil 
+/n.s 
*olive oil didn‟t 
prevent growth 
(Preuss et al. 2005) 
 
Olive oil +/n.s (Romero et al. 2007) 
Myrtus communis +/n.s (Deriu et al. 2007) 
n.s: not studied 
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3.1. Lemongrass Oil 
 
Lemongrass (Cymbopogon citratus) belongs to a family of fragrant grasses, of 
Indian origin, which includes palmarosa (Cymbopogon martinii) and citronella 
(Cymbopogon nardus); lemongrass is a tall grass which grows up to 5 feet high within a 
short period of time. It produces a network of roots and rootlets that rapidly exhaust the 
soil. It is now a cultivar of many tropical countries including central Africa, Sri Lanka, 
Brazil, Madagascar, Vietnam and Malaysia. 
Lemongrass oil is extracted from the fresh or partly dried leaves by steam 
distillation. It has a lemony, sweet smell and is dark yellow to amber and reddish in 
color, with a watery viscosity. The main chemical components of lemongrass oil are 
myrcene, citronellal, geranyl acetate, nerol, geraniol, neral and traces of limonene and 
citral (Ohno et al., 2003).  
The therapeutic properties of lemongrass oil are analgesic, anti-depressant, 
antimicrobial, antipyretic, antiseptic, astringent, bactericidal, carminative, deodorant, 
diuretic, febrifuge, fungicidal, galactagogue, insecticidal, nervine, nervous system 
sedative and tonic. It is a great overall tonic for the body and it boosts the 
parasympathetic nervous system, which is a boon when recovering from illness, as it 
also stimulates glandular secretions. It is useful with respiratory infections such as sore 
throats, laryngitis and fever and helps prevent spreading of infectious diseases. It is 
helpful with colitis, indigestion and gastro-enteritis. Lemongrass essential oil has anti 
microbial property which makes it inhibit microbial and bacterial growth in the body, 
internally or externally. It is seen to be effective in inhibiting bacterial infections in 
colon, stomach, urinary tracts, wounds, respiratory system etc. and helps cure diseases 
resulting from bacterial or microbial infections such as typhoid, food poisoning, skin 
diseases, malaria (caused by protozoon) etc (Maizura et al., 2007). It has been shown 
that lemongrass inhibited the growth of all H. pylori strains studied (either antibiotics-
susceptible or –resistant strains), even at a concentration of 0.01% (v/v) (Ohno et al., 2003). 
 
3.2. Clove Leaf Oil 
 
Clove essential oil is extracted from Eugenia caryophyllata (also known as 
Syzygium aromaticum, Eugenia aromatica, E. carophyllus) of the Myrtaceae family. 
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Clove oil has a warm, strong, spicy smell and the oil is colorless to pale yellow with a 
medium to watery viscosity. Clove oil can be extracted from the leaves, stem and buds. 
We sell clove leaf oil, which is extracted by water distillation, containing the desired 
lower percentage of eugenol. The main chemical components of clove oil are eugenol, 
eugenol acetate, iso-eugenol and caryophyllene (Lawless, 1995). 
The therapeutic properties of clove oil are analgesic, antiseptic, antispasmodic, 
anti-neuralgic, carminative, anti-infectious, disinfectant, insecticide, stimulant, 
stomachic, uterine and tonic (Fu et al., 2009). Clove oil can be used for acne, bruises, 
burns and cuts, keeping infection at bay and as a pain reliever. It helps with toothache, 
mouth sores, rheumatism and arthritis. It is beneficial to the digestive system, effective 
against vomiting, diarrhea, flatulence, spasms and parasites, as well as bad breath. 
Clove oil is valuable for relieving respiratory problems, like bronchitis, asthma and 
tuberculosis. The disinfecting property is useful in cases of infectious diseases. It is 
considered safe in very small quantities (<1500 p.p.m.) as a food additive (Bruneton, 
1995).  
 
3.3. Lemon Oil 
 
Lemon essential oil is extracted from the Citrus limonum (also known as Citrus 
Limon), of the Rutaceae family and is also known as cedro oil (which refers to 
terpeneless oil). Lemon oil is extracted from the fresh fruit peel by cold expression. 
Lemon oil has a sharp, fresh smell, is pale greenish-yellow in color and is watery in 
viscosity. The main chemical components of lemon oil are a-pinene, camphene, b-
pinene, sabinene, myrcene, a-terpinene, linalool, b-bisabolene, limonene, trans-a-
bergamotene, nerol and neral. It is non toxic (Hayes and Markovic, 2002).  
The therapeutic properties of lemon oil are anti-anemic, antimicrobial, anti-
rheumatic, anti-sclerotic, antiseptic, bactericidal, carminative, cicatrisant, depurative, 
diaphoretic, diuretic, febrifuge, haemostatic, hypotensive, insecticidal, rubefacient, tonic 
and vermifuge. Lemon oil can be very beneficial to the circulatory system and aids with 
blood flow, reducing blood pressure and helping with nosebleeds. It can help bring 
down fever, helps relieve throat infections, bronchitis, asthma and flu. It boosts the 
immune system and cleanses the body, improves the functions of the digestive system, 
and it is helpful with constipation, dyspepsia and cellulite. Lemon oil soothes and 
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relieves headaches and migraines and is helpful for rheumatism and arthritis. It is also 
used for clearing acne, cleaning greasy skin and hair, as well as removing dead skin 
cells, easing painful cold sores, mouth ulcers, herpes and insect bites (Duccio et al., 
1998). 
 
3.4. Thyme Oil 
 
Thyme oil is obtained from Thymus vulgaris (also known as Thymus aestivus, T. 
ilerdensis and T. velantianus) of the Labiatae family and is also known as common or 
red thyme. It is extracted from the fresh or partly dried flowering tops and leaves of the 
plant by water or steam distillation and the yield is 0.7 -1.0 %. It has a rather sweet, yet 
strongly herbal smell and is reddish-brown to amber in color. The oil is mainly located 
in small glands on the leaves and contains thymol, paracymene & linalool. Its chemical 
components are a-thujone, a-pinene, camphene, b-pinene, p-cymene, a-terpinene, 
linalool, borneol, b-caryophyllene, thymol and carvacrol. The essential oil of common 
thyme (Thymus vulgaris) is made up of 20-54% thymol. Thymol, an antiseptic, has been 
extensively documented for its antibacterial, antiviral, and anti-fungal action. According 
to Valnet, 1990, thyme oil kills the anthrax bacillus, the typhoid bacillus, 
meningococcus, and the agent responsible for tuberculosis and is active against 
salmonella and staphylococcus bacteria. In addition, this component has been studied 
for its effects on gingivitis and plaque-caused organisms in the mouth (Valnet, 1990). It 
has also been shown to be effective against the fungus that commonly infects toenails 
(Ramsewak et al., 2003). 
The therapeutic properties of thyme oil are antirheumatic, antiseptic, 
antispasmodic, bactericidal, bechic, cardiac, carminative, cicatrisant, diuretic, 
emmenagogue, expectorant, hypertensive, insecticide, stimulant, tonic and vermifuge. 
Thyme oil strengthens the nerves, aids memory and concentration, can help with the 
feeling of exhaustion and combats depression, while it fortifies the lungs and helps with 
colds, coughs, asthma, laryngitis, sinusitis, sore throats and tonsillitis. Thyme oil is 
beneficial to boost the immune system and can help fight colds, flu, infectious diseases 
and chills and as a urinary antiseptic, it is very helpful for cystitis and urethritis 
(Bruneton, 1995). 
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3.5. Cinnamon Bark Oil 
 
Cinnamon, which has the scientific name Cinnamomum zeylanicum, has 
originated from tropical Asia, especially Sri Lanka and India. Now the shrub is grown 
in almost every tropical region of the world. The herb, owing to its vast medicinal uses, 
had found a prominent position in traditional medicines, especially Ayurveda (the 
traditional Indian medicinal system). Traditionally cinnamon, due to its medicinal 
properties, has been used in many cultures for treating a variety of health disorders 
including diarrhea, arthritis, menstrual cramps, heavy menstruation, yeast infections, 
colds, flu, and digestive problems. The most widely used part of cinnamon is its bark. 
Steam distillation is the mostly adopted technology for production of cinnamon bark oil. 
However, there are occasional moves for the  extraction with Super Critical Carbon 
dioxide (CO2 Extracts) for quality markets.  
Today cinnamon bark oil is one of the most powerful antibacterial, antifungal, 
antiviral oils of all-even stronger than most antibiotics (Tung et al., 2010; Cava et al., 
2007). This oil is a powerful antioxidant. It may also be beneficial for circulation, 
infections, coughs, exhaustion, respiratory infections, digestion, rheumatism, and warts. 
This is a warming oil for the spirit as well as for the body. It restores wakefulness in the 
presence of fatigue. It is vitalizing, refreshing as well as warming. The warm glow of 
cinnamon helps transform sorrow into happiness. For emotional healing, it is used to 
encourage invigoration, benevolence, strength, and energy. Cinnamon bark oil 
possesses the delicate aroma of the spice with a sweet and pungent taste. Cinnamon 
bark oils major constituent is cinnamaldehyde but other, minor components impart the 
characteristic odour and flavour that is world renowned. It is employed mainly in the 
flavoring industry where it is used in meat and fast food seasonings, sauces and pickles, 
baked goods, confectionery, cola-type drinks, tobacco flavors and in dental and 
pharmaceutical preparations (Rose, 1992). 
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CHAPTER 4 
 
CHITOSAN IN DRUG DELIVERY SYSTEMS 
 
4.1. Sources, Structure, and Physicochemical Properties of Chitosan 
 
Chitin, which is the most abundant biopolymer in nature after cellulose, is a 
principal component of exoskeletons of crustaceans and insects as well as of cell walls 
of some bacteria and fungi. Chitosan is derived from of the chitin and is produced by 
partial alkaline deacetylation of chitin to form the polymer of acetyl glucosamine. The 
primary unit of chitosan is 2-amino-2-deoxy-D-glucose and with β→1-4 glucosidic 
linkages polymer chain is formed. Depending on its degree of deacetylation, the 
structure of chitosan includes 2-acetamido-2-deoxy-D-glucose. The chemical structure 
of chitosan is given in Figure 4.1.  
 
 
Figure 4.1. Chemical structure of chitosan with X=degree of deacetylation and 
n=number of sugar units per polymer (Source: Dodane and Vilivalam, 
1998). 
 
Chitosan is a polycationic polymer that has one amino group and two hydroxyl 
groups in the repeating glucosidic residue. The carbohydrate backbone is very similar to 
cellulose, which consists of β→1-4 -linked D-glucosamine. An important difference to 
cellulose is that chitosan is composed of acetylamino groups on the structure (Figure 
4.2) (Dash et al., 2011).  
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Figure 4.2. Chemical structures of cellulose (a), Chitosan (b) and chitin (c) 
(Source: Jayakumar et al., 2010). 
 
Chitin is second most abundant polymer in nature. However, applications of 
chitin are limited compared to chitosan because chitin is chemically inert. Due to its 
poor solubility in aqueous solution and organic solvents, it does not find practical 
applications whereas chitosan as an artificial variant of chitin is more suitable for useful 
bioapplications. So, chemically modified chitosan has multidimensional properties and 
a wide range of applications in biomedical and other industrial areas. 
Acetamide group of chitin can be converted into amino group to give chitosan, 
which is carried out by treating chitin with concentrated alkali solution. The treatment 
of chitin with an aqueous 40–45% (w/v) NaOH solution at 90–120 ºC for 4–5 h results 
in deacetylation of chitin (Dash et al., 2011). The conditions used for deacetylation 
determines the polymer molecular weight and the degree of deacetylation.  
Chitin and chitosan represent long-chain polymers having molecular mass up to 
several million Daltons. Chitosan is relatively reactive and can be produced in various 
forms such as powder, paste, film, fiber, etc. (Agnihotri et al., 2004). Commercially 
available chitosan has an average molecular weight ranging between 3800 and 20,000 
Daltons and is 66% to 95% deacetylated. 
The active primary amino groups on the molecule being reactive provide sites 
for a variety of side group attachment employing mild reaction conditions (Figure 4.3). 
Chitosan, being a cationic polysaccharide in neutral or basic pH conditions, contains 
free amino groups and hence, is insoluble in water. In acidic pH, amino groups can 
undergo protonation thus, making it soluble in water. Solubility of chitosan depends 
upon the distribution of free amino and N-acetyl groups. Usually 1–3% aqueous acetic 
acid solutions are used to solubilize chitosan. Chitosan is also soluble in dilute nitric and 
hydrochloric acids, marginally soluble in 0.5% phosphoric acid and insoluble in sulfuric 
acid at room temperature. 
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Figure 4.3. Schematic illustration of chitosan‟s versatility. At low pH (less than about 
6), chitosan‟s amine groups are protonated (because amine group has a pKa 
value of 6.3) conferring polycationic behavior to chitosan. At higher pH 
(above about 6.5), chitosan‟s amines are deprontonated and reactive 
(Source: Dash et al., 2011). 
 
Chitosan a linear polyelectrolyte at acidic pH, is soluble in variety of acids and 
interacts with polyanionic counterions. It forms gels with a number of multivalent 
anions. It has a high charge density i.e. one charge per glucosamine unit. Since many 
minerals carry negative charges, the positive charge of chitosan interacts strongly with 
negative surfaces. Chitosan is a linear polyamine where amino groups are readily 
available for chemical reactions and salt formation with acids. 
The attached side groups on chitosan provide versatile materials with specific 
functionality, alter biological properties or modify physical properties. For example, the 
characteristic features of chitosan such as being cationic, hemostatic and insoluble at 
high pH, can be changed by sulfating the amine group which makes the molecule 
anionic and water-soluble (Suh and Matthew, 2000).  
The important characteristics of chitosan are its molecular weight, viscosity, 
deacetylation degree (DA) crystallinity index, number of monomeric units (n), water 
retention value, pKa and energy of hydration. 
A linear unbranched structure and high molecular chitosan is an excellent 
viscosity enhancing agent in acidic environments. The viscosity of chitosan solution 
increases with an increase in the concentration of chitosan, decrease in temperature and 
with increasing degree of deacetylation. Viscosity also influences biological properties 
such as wound-healing properties (Altiok et al., 2010) and osteogenesis enhancement as 
well as biodegradation by lysozyme (Dash et al., 2011). 
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4.2. Biological Properties of Chitosan 
 
Chitosan has been widely used in medical and pharmaceutical applications 
because they have interesting properties that make them suitable for use in the 
biomedical field, such as biocompatibility, biodegradability and non toxicity. Moreover, 
other properties such as analgesic, antitumor, hemostatic, hypocholesterolemic, 
antimicrobial, and antioxidant properties have also been reported (Aranaz et al., 2009, 
Gobin et al., 2005, Gonzalez et al., 1999). The majority of the biological properties are 
related to the cationic behaviour of chitosan, the parameter with a higher effect is the 
degree of deacetylation. However, in some cases (Dash et al., 2011), the molecular 
weight has a predominant role. 
Chitosan can be degraded by several proteases (lysozyme, papain etc.). Besides, 
chitosan degrades under the action of fermentation and it is nontoxic and easily 
removable from the organism without causing concurrent side reactions. Their 
biodegradation leads to the release of non-toxic oligosaccharides of variable length 
which can be subsequently incorporated to glycosaminoglycans and glycoproteins, to 
metabolic pathways or be excreted (Aranaz et al., 2009). The degradation of chitosan by 
enzymatic reaction depends on the degree of deacetylation and length of the chain 
(molecular weight of the chitosan), because the number and distribution of acetyl 
groups affects biodegradability. 
Chitosan is biocompatible with living tissues since it does not cause allergic 
reactions and rejection. It breaks down slowly to harmless products (amino sugars), 
which are completely absorbed by the human body (Dash et al., 2011). However, fast 
degradation rates will cause accumulation of amino sugars and hence cause inflamatory 
response (Aranaz et al., 2009). Chitosan absorbs the proton ion released in the 
inflammatory area and thus has the main analgesic effect. The free amino groups of 
chitosan can protonate in the presence of proton ion and the reduction in pH is the main 
cause of the analgesic effect.  
Chitosan possesses antimicrobial property and absorbs toxic metals like 
mercury, cadmium, lead, etc. The polycationic structure of chitosan is responsible for 
the antimicrobial activity of chitosan. As environmental pH is below the pKa of the 
chitosan, electrostatic interactions between the polycationic structure of the chitosan and 
anionic components of the microorganisms‟ surface plays a primary role (Kong et al., 
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2010). Thus, the number of amino groups in chitosan structure is important in 
electrostatic interaction, which strongly depends on the degree of deacetylation. Large 
amount of amino groups are able to enhance the antimicrobial activity. As 
environmental pH is above pKa, hydrophobic and chelating effects are responsible for 
antimicrobial activity. In another study, Aranaz et al. (2009) reported that the 
degradation product of the chitosan has important role to inhibit the microorganisms 
and has more antimicrobial activities than the chitosan. 
Chitosan has shown a significant scavenging capacity against different radical 
species, the results being comparable to those obtained with commercial antioxidants. 
Samples prepared from crab shell chitin with degree of deacetylation of 90, 75 and 50% 
where evaluated on the basis of their abilities to scavenge 1,1-diphenyl-2-picrylhydrazyl 
(DPPH) radical, hydroxyl radical, superoxide radical and alkyl radical. The results 
revealed that chitosan with higher DD exhibited the highest scavenging activity (Park et 
al., 2004). The chelation of metal ions is one of the reasons why chitosan may be 
considered as a potential natural antioxidant for stabilizing lipid containing foods. Both 
degree of deacetylation and molecular weight of the chitosan affect on the antioxidative 
property of the chitosan and it increases by increasing the number of amino groups in 
chitosan structure.  
An antitumor activity of chitosan has been claimed by inhibition of the growth 
of tumor cells mainly due to an immune stimulation effect. Jeon and Kim (2002) have 
found that chitosan oligomers possess antitumor activities tested both in vitro and in 
vivo. Studies carried out using mice that had ingested low-molecular weight chitosan 
revealed significant antimetastatic effects of chitosan against Lewis lung carcinoma. 
Chitosan is one of the mucoadhesive polymers that may fulfill the desirable 
features of a prolonged residence time at the site of drug absorption owing to increased 
contact with the mucosa, resulting in localization in specified regions to improve the 
bioavailability of drugs (Pedro et al., 2009). The mucus is composed of a glycoprotein 
called mucin, which is rich in negative charges since it has sialic acid residues (He et 
al., 1998). In the stomach, chitosan is positively charged due to the acidic environment 
and, therefore, it can interact with mucin by electrostatic forces. This mucoadhesive 
property of the chitosan lets use it as drug delivery systems in gastrointestine. The 
extent of this union depends on the amount of sialic acid present in the mucin (He et al., 
1998) and on the molecular weight and degree of deacetylation of chitosan. It has been 
found that when the molecular weight of chitosan increases, the penetration in the 
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mucin layer also increases and hence the mucoadhesion is stronger (Lehr et al., 1992). 
On the other hand, a higher degree of deacetylation leads to an increase in charge 
density of the molecule and the adhesive properties become more relevant (He et al., 
1998). 
Additionally, because of the beneficial properties of the chitosan, it has found 
wide applications in many industries such as in cosmetics as a fungicide and viscosity 
enhancer, in opthalmology for contact lenses, in environmental protection as the aid for 
heavy metal removal, and color removal from textile mill effluents, in food as 
antimicrobial and antioxidative agent, 
 
4.3. Biomedical Applications of Chitosan 
 
Due to its high biocompatibility, chitosan has been employed in drug delivery 
systems, surgical dressings, implantable and injectable systems such as orthopaedic and 
periodontal composites, wound healing management and scaffolds for tissue 
regeneration.  
 
4.3.1. Wound Dressing Material 
 
Chitosan oligomers have also exhibited wound-healing properties, it is 
suggested that their wound-healing properties are due to their ability to stimulate 
fibroblast production by affecting the fibroblast growth factor. Subsequent collagen 
production further facilitates the formation of connective tissue (Kweon et al., 2003, 
Wittaya-areekul and Prahsarn., 2006, Ishihara et al., 2002). Recently, the use of natural 
bioactive compounds, such as essential oils have been used in wound healing 
application. Chitosan‟s wound healing property together with both thyme oil‟s 
antimicrobial activity and the role of thymol (active compound in thyme oil) in wounds 
make it possible to have functional wound healing material (Altiok et al., 2010).  
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4.3.2. Drug Delivery Systems 
 
An important application of chitosan in industry is the development of drug 
delivery systems such as nanoparticles, hydrogels, microspheres, films and tablets. If 
degree of deacetylation and molecular weight of chitosan can be controlled, then it 
would be a material of choice for developing micro/nanoparticles. Chitosan has many 
advantages, particularly for developing micro/nanoparticles. These include; 
 its ability to control the release of active agents, it avoids the use of 
hazardous organic solvents while fabricating particles since it is soluble 
in aqueous acidic solution,  
 it is a linear polyamine containing a number of free amine groups that are 
readily available for crosslinking,  
 its cationic nature allows for ionic crosslinking with multivalent anions,  
 it has mucoadhesive character, which increases residual time at the site 
of absorption,  
  it prolongs the duration of drug activity and improves therapeutic 
efficiency, 
 it reduces side effects, 
 it has very low toxicity; LD50 of chitosan in laboratory mice is 16 g/kg 
body weight, which is close to sugar or salt.  
 it is possible to use various sterilization methods such as ionizing 
radiation, heat, steam and chemical methods can be suitably adopted for 
sterilization of chitosan in clinical application.  
In view of the above-mentioned properties, chitosan is extensively used in 
developing drug delivery systems. Particularly, chitosan has been used in the 
preparation of mucoadhesive formulations (Nascimento et al., 2001; Obara et al., 2005; 
Falk et al., 2004; Guo et al., 2007), improving the dissolution rate of the poorly soluble 
drugs (Gobin et al., 2005; Jain et al., 2007, Bigia et al., 2002), drug targeting (Ekici and 
Saraydin, 2007; Yuan et al., 2007) and enhancement of peptide absorption (Obara et al., 
2005; Falk et al., 2004; Bigia et al., 2002). 
The achievement of predictable and reproducible release of an agent into a 
specific environment over an extended period of time has much significant subject. It 
creates a desired environment with optimum response, minimum side-effects and 
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prolonged efficiacy (Figure 4.4). Controlled release dosage forms enhance the safety, 
efficacy and reliability of drug theraphy. 
Generally, a drug is administered in a high dose at a given time only to repeat 
that dose several hours or days later (Figure 4.4). This conventional dosage forms often 
leads to wide swings in serum drug concentrations. Most of the drug content isi released 
soon after administration, causing drug levels in the body to rise rapidly, peak and 
decline sharply. Those sharp fluctuations often cause unacceptable side effects at the 
peaks, followed by inadequate theraphy. On the other hand, controlled release of the 
drug can eliminate the overdose of the drug in plasma, and accordingly side effects, so 
effective theraphy is observed. Besides this, many drugs have beneficial effects when 
they are delivered slowly over a prolonged period. As a consequence, increasing 
attention has been focused on methods of giving drugs continually for prolonged time 
periods and in a controlled fashion.  
 
 
Figure 4.4. Comparison of the high dose administration (IR) and prolonged controlled 
release (CR) of the drug. Effective theraphy is achieved without any side 
effects by CR. 
 
 
The primary method of accomplishing this controlled release has been through 
incorporating the drugs within polymers. The optimal carrier would preserve the 
biological activity of drug and prevent its rapid release. Because of the beneficial 
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biological and physical properties of the chitosan, it can be good candidate for the drug 
carrier systems.  
The primary hydroxyl and amine groups located on backbone of chitosan allow 
chemical modification to control its physical properties. When the hydrophobic moiety 
is conjugated to a chitosan molecule, the resulting amphiphile may form self assembled 
nanoparticles that can encapsulate a quantity of drugs and deliver them to a specific site 
(Park et al., 2010). Chemical attachment of the drug to the chitosan throughout the 
functional linker may produce useful systems, exhibiting the appropriate biological 
activity at the target site. Additionally, mucoadhesive and absorption enhancement 
properties of chitosan increase the in vivo residence time of the dosage form in the 
gastrointestinal tract and improve the bioavailability of various drugs. 
Chitosan is used in drug delivery system in many forms, such as hydrogels, 
tablets, and transdermal delivery forms and as microcapsules and nanoparticules.  
 
4.3.2.1. Microsphere Production Techniques 
 
Different methods have been employed to prepare chitosan particulate systems. 
Figure 4.5. summarizes the methods most widely applied to produce microspheres. For 
selection of any of the methods one should take into consideration factors such as 
particle size requirement, thermal and chemical stability of the active agents, 
reproducibility of the release kinetic profiles, stability of the final product, residual 
toxicity associated with the final products, the nature of the active molecule as well as 
the type of the delivery device. 
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Figure 4.5. Methods for preparation of chitosan microspheres. 
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4.3.2.1.1. Ionotropic gelation 
 
In this method, chitosan solutions in acetic acid are prepared and extruded drop 
wise through a needle into different concentrations of aqueous solutions of magnetically 
stirred counterions such as tripolyphosphate, alginate, lauryl sulphate etc. The beads are 
removed from the counter ion solution by filtration, washed with distilled water, dried 
by an air jet and further air dried at ambient temperature (Agnihotri et al., 2004).  
 
4.3.2.1.2. Wet Phase Inversion 
 
In this method of preparation, chitosan solution in acetic acid is dropped into an 
aqueous solution of a counterion sodium tripolyphosphate through a nozzle. 
Microspheres formed are allowed to stand for 1 h, washed and crosslinked with 5% 
ethylene glycol diglycidyl ether. Finally, the microspheres are washed and freeze-dried 
to form porous chitosan microshperes (Mi et al., 1999). Changing the pH of the 
coagulation medium could modify the pore structure of the chitosan microsphere. 
 
4.3.2.1.3. Emulsification and Ionotropic Gelation 
 
This method exploits the reactive functional amine group of chitosan to cross-
link with the available reactive groups of the cross-linking agent. A suitable surfactant 
is used to stabilize the aqueous droplets. In this method the dispersed phase, which 
consists of an aqueous solution of chitosan, is added to a non-aqueous continous phase 
(emulsifer) to form a water-in-oil (w/o) emulsion. Sodium hydroxide solution is then 
added at different intervals leading to ionotropic gelation. The microspheres thus 
formed are removed by filtration, washed and dried. This method, is helpful in 
controlling the size of the particles by controlling the size of aqueous droplets. 
However, the particle size of final product is dependent on the extent of cross-linking 
agent used while hardening along with the speed of stirring.  
The emulsion cross-linking method involves a few drawbacks. Besides being 
tedious it uses harsh cross-linking agents, which might possibly induce chemical 
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reactions with the active agent. Moreover, complete removal of the unreacted cross-
linking agent may be a challenge. 
 
4.3.2.1.4. Coacervation and Complex Coacervation 
 
In this process, the polymer is solubilized to form a solution. This is followed by 
addition of a solute, which forms insoluble polymer derivative and precipitates the 
polymer. This process avoids the use of toxic organic solvents and glutaraldehyde used 
in the other methods of preparation of chitosan microspheres. Chitosan microparticles 
can also be prepared by complex coacervation. Sodium alginate, sodium 
carboxymethylcellulose, κ-carregeenan and sodium polyacrylic acid can be used for 
complex coacervation with chitosan to form microspheres (Sinha et al., 2004). These 
microparticles are formed by interionic interaction between oppositely charged 
polymers. Formulation of coacervate capsules of chitosan–alginate and chitosan–κ- 
carrageenan was carried out by interaction of the above-mentioned solutions with 
potassium chloride and calcium chloride, respectively. The obtained capsules were 
hardened in the counterion solution before washing and drying. 
The physicochemical property of chitosan is utilized in this method since it is 
insoluble in alkaline pH medium, thus precipitates/coacervates when it comes in contact 
with alkaline solution. Chitosan solution is blown into an alkali solution like sodium 
hydroxide, NaOH–methanol or ethanediamine using a compressed air nozzle to form 
coacervate droplets (Dash et al., 2011). Separation and purification of particles are 
performed by filtration/centrifugation followed by successive washing with hot and cold 
water. The method is schematically represented in Figure 4.6. Variation in compressed 
air pressure or spray-nozzle diameter can be done to control the size of the particles. 
The drug release can be controlled by using appropriate cross-linking agent. 
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Figure 4.6. Schematic representation of preparation of chitosan particulate systems by 
coacervation/precipitation method (Source: Sinha et al., 2004). 
 
4.3.2.1.5. Coating by Chitosan 
 
In this method, previously formed microparticles are coated with chitosan. 
Microspheres are prepared and added to various concentrations of chitosan acetic acid 
solutions and mixed; the chitosan treated microspheres are filtered and dried. 
 
4.3.2.1.6. Thermal Crosslinking 
 
In this method, crosslinking agent is added to an aqueous acetic acid solution of 
chitosan and chitosan crosslinked solution is cooled to 0 ºC. Than, this emulsion is 
added to liquid paraffin oil maintained at 120 ºC and crosslinking is performed (Koradia 
et al., 2009). The microspheres obtained are filtered and washed with diethyl ether, 
dried at room temperature.  
 
4.3.2.1.7. Solvent Evaporation Technique 
 
The solvent evaporation technique to produce microcapsules is applicable to 
wide variety of core materials. This method involves the formation of an emulsion 
between polymer solution and an immiscible continuous phase whether aqueous (o/w) 
or non-aqueous (w/o). Chitosan dissolved in an aqueous acetic acid solution. The 
solution is added to toluene and sonicated to form a w/o emulsion. Glutaraldehyde 
solution in toluene is added to the emulsion and stirred at room temperature to give 
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cross-linked microspheres. The suspension is centrifuged. Following evaporation of the 
solvent, the microspheres are separated, washed with distilled water and dried. Here 
system is warmed to 50 ºC and the pressure is reduced. When the solvent is evaporated 
completely the microspheres are separated, washed with sodium hydroxide solution, 
distilled water and diethyl ether and dried. 
 
4.3.2.1.8. Spray Drying 
 
Spray drying is one of the microencapsulation technique in which an active 
material is dissolved or suspended in a melt or polymer solution and becomes trapped in 
the dried particle. Although several methods are available for the preparation of 
microparticles, spray drying is widely used in the pharmaceutical industry and has been 
used to produce dry powders, granules, or agglomerates from drug-excipient solutions 
and suspensions (Gonzalez et al. 1999). This technique can be used either for both heat-
resistant and heat-sensitive drugs or for both water-soluble and water-insoluble drugs or 
for both hydrophilic and hydrophobic polymers. The main advantage of spray drying is 
the ability to handle labile materials because of the short contact time in the dryer, in 
addition, it is a one-stage continuous process, easy to scale-up, and only slightly 
dependent upon solubility of drug and polymer. The particle size of the microspheres 
prepared by the spray-drying method ranged from a micron to several tens of microns 
and had a relatively narrow distribution (Desai and Park 2005).  
In a spray drying process, a liquid feed is dried with a hot gas. This hot gas is 
generally air which is replaced by nitrogen for drying sensitive materials such as 
pharmaceuticals, and solvents like ethanol. The liquid feed may be a solution, colloid or 
suspension.The method is based on drying of atomized droplets in a stream of hot air. 
Briefly, chitosan is dissolved in aqueous acetic acid solution, drug is then dissolved or 
dispersed in the solution followed by the addition of a suitable cross-linking agent. This 
solution or dispersion is then atomized in a stream of hot air that leads to the formation 
of small droplets, from which solvent evaporates instantaneously leading to the 
formation of free flowing particles (Figure 4.7). 
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Figure 4.7. Schematic representation of preparation of particulate system by spray 
drying metod.  
 
Selection of the atomiser (nozzle) is one of the most important choices in spray 
dryer design and has a significant effect upon the size distribution of the final dried 
particles. The most important atomiser characteristics from the standpoint of product 
quality are uniformity of drop-size, control of drop-size distribution, and homogeneity 
of the spray. Atomisers common forms are pressure atomisers, centrifugal (wheel) 
atomisers and pneumatic (two-fluid) atomisers (Re, 1998). Drying process conditions, 
such as dryer inlet and outlet air temperatures, drying air velocity, solution feed rate, 
dryer feed temperature, humidity of the dryer inlet air etc. directly influence on the 
either physicochemical properties (shape, mean particle size, integrity, porosity, bulk 
volume ec.) of the final microparticles (Masters, 1985) and biological activities of 
encapsulated active materials. Accordingly, properties of encapsulated materials 
(molecular weight, vapor pressure, concentration in the emulsion), properties of the 
capsule material (type and molecular weight, chemical interactions with the active 
compounds), properties of the emulsion (dissolved solids content, viscosity, oil droplet 
size distribution etc.) should influence the final microspheres‟ properties (Re, 1998).   
In comparison with a wide variety of microencapsulation techniques, spray 
drying may offer the advantage of realising the microencapsulation process in one step. 
In addition, it seems to come close to the properties desired for an ideal method of 
preparation of controlled release microparticles: spray drying offers rapidity, little 
dependency on the solubility characteristics of the drug and polymer, and is easy to 
scale up (Re, 1998). From these considerations, the evaluation of the spray drying as a 
method for encapsulation of drugs has been a research area of increasing interest.  
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A number of articles have been published describing the preparation of 
microspheres by such spray drying methods. For example, microspheres composed of 
chitosan were prepared for the delivery of cimetidine, famotidine, nizatidine (He et al., 
1999) and vitamin C (Desai et al., 2006). Glutaraldehyde was used in most of the 
studies as a crosslinking agent (He et al., 1999; Desai et al., 2006). In Table 4.1, the 
drug release studies were summarized in which the microspheres were formed by spray 
drying. The particle size of the microspheres prepared by spray drying method ranged 
from a few microns to several tens of microns, and had a relatively narrow distribution. 
The microspheres were positively charged in order to enhance the mucoadhesive 
properties and make these suitable for delivery of drugs via the nasal or gastrointestinal 
routes of delivery (He et al., 1999).  
 
Table 4.1. Microspheres prepared by spray drying for drug release 
 
Polymer Crosslinker Drug Released Reference 
Chitosan chondroitin sulphate formaldehyde 
metoclopramide 
hydrochloride 
Gonzalez et al., 
1999 
Chitosan 
glutaraldehyde 
or formaldehyde 
cimetidine, 
famotidine, 
nizatidine 
He et al., 1999 
Gelatin glutaraldehyde 
salmon 
calcitonin 
Desai et al., 
2006 
Chitosan, hydroxypropyl-
methylcellulose, 
hydroxypropylcellulose, 
sodium alginate 
 
- 
 
Levocetirizine 
dihydrochloride 
 
Rathananand et 
al., 2007 
5-methylpyrrolidinone 
chitosan 
- 
metoclopramide 
hydrochloride 
Gavini et al., 
2008 
chitosan/b-cyclodextrin - theophylline 
Zhang et al., 
2008 
sodium hyaluronate - piroxicam 
Piao et al., 
2007 
bovine serum albumin glutaraldehyde gentamicin 
Haswani et al., 
2006 
hydroxypropyl 
methylcellulose, chitosan, 
carbopol 934P 
 
- 
 
Propranolol 
HCl 
Harikarnpakdee 
et al., 2006 
chitosan tripolyphosphate Vitamin C 
Desai et al., 
2006 
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There are number of articles describing the oil encapsulation by spray drying 
with different wall materials. In these studies, encapsulations of oils by spray drying 
were performed in order to preserve aroma components of them for food applications. 
However, it would be very beneficial to investigate these studies since, in most of these 
studies, spray drying conditions were investigated and effects of drying conditions were 
analyzed. These studies were summarized in Table 4.2. Generally, 180 °C of inlet 
temperature was chosen for microsphere production but some studies pointed out the 
effect of inlet temperature on microsphere‟s properties (Turchiuli et al., 2005; 
Klinkesorn et al., 2006; Fuchs et al., 2006; Drusch and Berg, 2008).  Feed rate and oil/ 
polymer ratio were significantly different in these studies. The optimization of these 
parameters strongly depends on the oil used as a model drug material. 
 
Table 4.2. Spray drying studies for oil encapsulation 
 
Polymer Oil Type 
Spray Drying 
Conditions 
Reference 
Chitosan and corn 
syrup solid 
Tuna oil 
(5%) 
Feed rate: 2.2 L/h 
Inlet T: 165, 180, 
195 °C 
(Klinkesorn et 
al. 2006) 
nOSA starch and 
glucose syrup 
Fish oil 
(30% and 50%) 
Inlet T: 160, 210 °C 
Outlet T: 60, 90 °C 
(Drusch and 
Berg 2008) 
maltodextrin and 
acacia gum 
 
Vegetable oil 
(5%(w/w dry 
matter) 
Feed rate: 22, 68 ml/min 
Inlet T: 200, 220°C 
Outlet T: 100, 130°C 
(Turchiuli et 
al. 2005) 
maltodextrin and acacia 
gum 
 
Vegetable oil 
(5%(w/w) 
Feed rate: 24, 68 ml/min 
Inlet T: 200, 220°C 
Outlet T: 100, 130°C 
(Fuchs et al. 
2006) 
whey protein isolate/ 
maltodextrin 
 
Avocado oil 
50% (w/w) 
 
Feed rate: 1 kg/h 
Inlet T: 100°C 
Outlet T: 80°C 
(Bae and Lee 
2008) 
starch, gum arabic, 
sugar beet pectin, 
sodium caseinate, 
glucose, syrup 
Fish oil 
40% 
(w/w) 
Feed rate: 1-7 kg/h 
Inlet T: 180°C 
Outlet T: 70°C 
(Drusch et al. 
2007) 
Methylcellulose 
Maltodextrin 
Fish oil 
Wall:core ratio 
(3:1) (1.5:1) 
Feed rate: 15.0 g/min 
Inlet T: 160°C 
Outlet T: 65°C 
(Kolanowski 
et al. 2006) 
 
(Cont. on next page) 
 
 35 
Table 4.2. (cont.) 
 
modified starch 
 
Fish oil 
Oil:starch ratio 
(0.5:1), (1:1) 
(1.5:1) 
 
Inlet T: 150°C 
Outlet T: 80°C 
 
(Tan et al. 
2005) 
maltodextrin modified 
starch whey protein 
concentrate 
Fish oil 
1:4 (core:wall) 
 
Feed rate: 3kg/min 
Inlet T: 180°C 
Outlet T: 65°C 
(Jafari et al. 
2008) 
 
Although a dehydration process is successfully employed for the drying of oils 
to preserve the antioxidant activity, antimicrobial effect and aroma effect of oil‟s active 
components, spray drying can also be used as an oil encapsulation method for 
therapeutic purpose when it entraps active material within a protective matrix.  
 
4.4. Crosslinking of Chitosan 
 
For the preparation of chitosan particles, several techniques are available such as 
emulsion, ionotropic gelation, reverse micellar, solvent evaporation, spray drying, 
coacervation, and sieving methods (Desai and Park, 2005). A variety of hydrophilic and 
hydrophobic drugs can be loaded into the chitosan particles during the preparation of 
the microparticles, in which the loading efficiency of the drug may depend on its 
physicochemical characteristics and the preparation method.  
The cross-linked microparticles have often been prepared using the chitosan and 
its derivatives by exploiting their cationic nature, in which the amino groups of the 
chitosan backbone can interact with glutaraldehyde, sodium sulphate, tripolyphosphate 
(Park et al., 2010) and natural crosslinkers: genipin (Muzzarelli, 2009), vanillin (Peng et 
al., 2010) etc. The crosslinking may be achieved in acidic, neutral or basic environments 
depending on the method applied.  
Ionotropic gelation can be achieved by reaction of the amine group of the 
chitosan with tripolyphosphate, or hydrophobic counterions (e.g. alginate, carragenan 
etc.) and or high molecular weight ions (e.g. octyl sulphate, lauryl sulphate etc.) (Sinha 
et al., 2004). The chitosan solution in acetic acid is extruded dropwise through a needle 
into different concentrations of aqueous solutions of magnetically stirred 
tripolyphosphate or some other anion. The beads are removed from the counter ion 
solution by filtration, washed with distilled water and dried. Alternatively, wet phase 
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invasion, emulsification, coacervation methods can be used to obtain chitosan 
microspheres.  
Crosslinking agents such as glutaraldehyde and genipin have been widely used 
in most of the studies in literature for the preparation of chitosan microspheres. Possible 
chemical reactions between the chitosan-glutaraldehyde and chitosan-genipin are shown 
in Figures 4.5 and 4.6, respectively (Mi et al., 2001). 
 
 
Figure 4.5. Chitosan- glutaraldehyde crosslinking mechanism  
(Source et al., 2001). 
 
Glutaraldehyde is by far the most widely used agent in spite of some local 
cytotoxicity, due to its efficiency of stabilization of many biomaterials. Glutaraldehyde 
is easily available, inexpensive and its aqueous solutions can effectively crosslink 
collagenous tissues in a relatively short period. Glutaraldehyde reacts with chitosan 
(Figure 4.5) and it cross-links in an inter- and intra- molecular fashion through the 
formation of  covalent bonds mainly with the amino groups of the polysaccharide 
(Genta et al., 1998). However, if released into the host due to biodegradation, 
glutaraldehyde is toxic. This is the reason of the increasing demand for a crosslinking 
agent able to form stable and biocompatible crosslinked products, without added 
citotoxicity problems (Bigia et al., 2002; Shalaby and Burg, 2004). 
Genipin is obtained from its parent compound, geniposide, via enzymatic 
hydrolysis with glucosidase. Geniposide is isolated from the fruits of Genipa americana 
and Gardenia jasminoides Ellis and constitutes about 4–6% of dried fruit. Genipa 
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americana is found in tropical America, from Mexico and the Caribbean to Argentina, 
where it is widely planted for its shade and fruit. The fruits, with a taste similar to 
quinces, are eaten raw, used to make a sour, refreshing drink, cooked with sugar to 
flavor liquor, and used as a diuretic and as a remedy for respiratory ailments. Gardenia 
jasminoides plants are grown in the Far East, and their fruits have long been used in 
Chinese medicine for their anti-inflammatory, diuretic, choleretic, and haemostatic 
properties. Extracts from the fruits have also been used to form brilliant blue pigments 
via the reaction of genipin with primary amines in the presence of oxygen, which are 
used as a food dye commonly known as gardenia blue. These blue pigments are of 
particular importance because they are highly stable to heat, pH, and light. Initial 
observation of the formation of dimers of genipin in the presence of glycine led to the 
suggestion that genipin could be used to covalently crosslink proteins containing 
residues with primary amine groups. Subsequently, it has been used in studies of tissue 
fixation to crosslink collagen and gelatin, in foodstuff to crosslink soy protein isolates, 
and in studies of drug delivery, where it has been used to crosslink chitosan. Figure 4.6 
indicates the chemical reaction between the genipin and amino group of the chitosan.  
 
 
Figure 4.6. Chitosan-genipin crosslinking mechanism  
(Source: Mi et al., 2000). 
 
Varying amount of crosslinking agent directly effects the crosslinking density 
(Sinha et al., 2004). Additionally, it was found that the swelling ability of the 
crosslinked chitosan microspheres increased with the decrease of reaction time (Mi et 
al., 2000). This can be explained by the requirement of the time for the reaction between 
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the functional groups of the chitosan and croslinkers. Buttler et al. (2003) indicated the 
significance of the reaction time for achieving crosslinked genipin-chitosan structure. 
The lower swelling ability of chitosan gel is attributed to the increased intermolecular or 
intramolecular linkage of the –NH2 sites in chitosan, which could be achieved by a more 
complete crosslinking reaction. By maintaining the same reaction time for crosslinking 
and comparing the equilibrium swelling ratio of genipin crosslinked chitosan 
microsphere to that of the traditional glutaraldehyde-crosslinked one, it was found that 
the genipin-crosslinked chitosan microsphere has the higher swelling ability (Mi et al., 
2000). The result is ascribed to the slower gelation rate of genipin-crosslinked chitosan. 
Moreover, by measuring the viscosity changes in the chitosan solution during gelation, 
it was found that the viscosity of glutaraldehyde crosslinked chitosan solution increased 
significantly faster than that of the genipin-crosslinked one. Consequently, crosslinking 
of chitosan strictly depends on the crosslinker used, concentration of the crosslinker, 
crosslinking time and pH of the medium.  
Within the view of many applications, genipin can be chosen as crosslinking 
agent because of its markedly lower cytotoxicity as compared with alternative 
crosslinker, glutaraldehyde. It was found that genipin is about 5000–10,000 times less 
cytotoxic than glutaraldehyde (Yuan et al., 2007). Genipin has been widely used in drug 
release systems due to its promising properties. A number of studies were summarized 
in Table 4.3. 
 
Table 4.3. Studies with genipin as a crosslinker 
 
Polymers System Application Area Reference 
Chitosan Film Edible Film (Mi et al., 2006) 
Chitosan / poly (vinyl 
pyrrolidone) 
Hydrogel Characterization 
(Khurma et al., 
2005) 
Chitosan / poly (vinyl 
pyrrolidone) 
Hydrogel Characterization 
(Khurma et al., 
2006) 
chitosan/ poly 
(ethylene oxide) 
Film Characterization (Jin et al., 2004) 
Chitosan Film Characterization (Mi et al., 2005) 
 
(Cont. on next page) 
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Table 4.3. (cont.) 
 
Chitosan Hydrogel Drug delivery (Mi et al., 2008) 
Chitosan Microsphere 
Intramuscularly 
implantable drug-
delivery-vehicle 
(Mia et al., 2008) 
Chitosan/ gelatin Microsphere 
Drug- and 
immunotargeting 
(Mi, 2005) 
Chitosan/ alginate Beads Drug delivery (Mi et al., 2002) 
Gelatin Film Characterization (Bigi et al., 2002) 
Gelatin Hydrogel Characterization (Yao et al., 2004) 
Gelatin/ Fe3O4 
Magnetic 
Hydrogel 
Drug delivery (Liu et al., 2006) 
 
 
To eradicate the H. pylori, many studies have been performed and are listed in 
Table 4.4.  Amoxicillin, tetracycline and clarithromycin were used as antibiotics.  
 
Table 4.4. Antibiotic release systems for H. pylori theraphy. 
 
Polymer System 
Used 
Technique 
Crosslinking 
Agent 
Drug Source 
Chitosan 
Polyacrylic 
Acid 
Hydrogel Spray drying - Amoxicillin 
(Torre et 
al., 2003) 
Chitosan Microsphere Emulsification Glutaraldehyde Amoxicillin 
(Patel and 
Patel, 2007) 
Chitosan Microsphere Emulsification Glutaraldehyde Clarithromycin 
(Majithiya 
and 
Murthy, 
2005) 
Chitosan 
Polyacrylic 
Acid 
Hydrogel Spray drying - Amoxicillin 
(Torre et 
al., 2005) 
Chitosan Microsphere 
Ionic 
crosslinking/ 
Precipitation 
- Tetracycline 
(Hejazi and 
Amiji, 
2002) 
 
(Cont. on next page) 
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Table 4.4. (cont.) 
 
Chitosan Microsphere 
Chemical 
crosslinking/ 
Precipitation 
Glyoxal Tetracycline 
(Hejazi and 
Amiji, 
2004) 
Chitosan 
Poly (ethylene 
oxide) 
Hydrogel Spray drying Glyoxal 
Amoxicillin 
metranidazole 
(Patel and 
Amiji, 
1996) 
Chitosan 
Polyacrylic 
Acid 
Hydrogel Spray drying - Amoxicillin 
(Torrado et 
al., 2004) 
 
Patel ve Amiji (1996) aimed to develop a pH sensitive antibiotic release system 
for stomach using chitosan and poly(ethylen oxide) by crosslinking. Amoxicillin and 
metranidazole were used as model drugs and their release from the freeze dried 
hydrogels into SGF was studied. Within 2 hours, release of 65% amoxicillin and 59% 
metranidazole were successfully achieved. Hejazi ve Amiji (2002) tried to develop a 
stomach-specific drug delivery system to increase the efficacy of tetracycline against 
Helicobacter pylori. Chitosan microspheres were prepared by ionic cross-linking and 
precipitation with sodium sulfate. Maximum drug loading efficiency was achieved as 
69% (w/w). They found that thirty percent of tetracycline either in solution or when 
released from microspheres was found to degrade at pH 1.2 in 12 h. In another study by 
the same authors the effect of chemical crosslinking of chitosan microspheres on the 
gastric residence and local tetracycline concentrations was examined. Results of this 
study show that chitosan microspheres prepared by chemical crosslinking provide a 
longer residence time in the stomach than either tetracycline solution or microspheres 
prepared by ionic precipitation (Hejazi and Amiji, 2004). Chitosan-based mucoadhesive 
microspheres of clarithromycin was developed to provide prolonged contact time for 
drug delivery of antibiotics to treat stomach ulcers. Microspheres were prepared by 
emulsification technique using glutaraldehyde as a crosslinking agent and drug 
entrapment upto 74% was obtained. Extent of cross-linking exhibited an inverse 
relation to drug release rate as well as mucoadhesion, whereas polymer concentration 
exhibited an inverse correlation with drug release while linear relationship with 
mucoadhesion (Majithiya and Murthy, 2005).  
There are limited number of studies on the production of essential oil loaded 
microspheres and their controlled release profiles. Although there is no study for the H. 
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pylori eradication with essential oil loaded microspheres, citronella oil was 
encapsulated by chitosan using o/w emulsion method (Hsieh et al., 2006). The changes 
in concentration of chitosan affected the encapsulation efficiency of the volatile 
citronella oil. Furthermore, it was found that, the particle size of chitosan microcapsules  
decreased as the emulsification stirring speed increased. 
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CHAPTER 5 
 
THEORY OF CONTROLLED DRUG DELIVERY 
 
5.1. General Aspects 
 
Controlled drug delivery is the release of drug or other active agent in a 
predesigned manner from a material combined with them. The release of the active 
agent may be constant or cyclic over a long period, or it may be triggered by the 
environment. The purpose of controlled drug delivery is to achieve more effective 
therapies while eliminating the potential for both under- and overdosing. Other 
advantages of using controlled drug delivery systems are maintenance of optimum 
therapeutic drug concentration in the blood or in a cell, predictable and reproducible 
release rates for extended periods of time, enhancement of activity duration for short 
half-life drugs, the elimination of side effects, frequent dosing, and waste of drug, 
optimized therapy and better patient compliance. The ideal drug delivery system should 
be inert, biocompatible, mechanically strong, comfortable for the patient, capable of 
achieving high drug loading, safe from accidental release, simple to administer and 
remove, and easy to fabricate and sterilize (Boateng et al., 2007). 
In recent years, more sophisticated controlled drug delivery systems have been 
developed which are able to respond to changes in the biological environment and 
deliver drugs based on these changes. Also, the studies focusing on the targeting 
delivery systems in which the drug is to be delivered in a targeted cell, tissue or site 
have been carried on. (Lin et al., 2005; Polnok et al., 2004; Chena et al., 2004). 
The selection of a biomaterial for a specific application depends on the 
physicochemical properties and durability of the material, the nature of the 
physiological environment at the organ or tissue, adverse effects in case of failure, cost 
and production ease, biocompatibility, mechanical strength, sterilization requirement, 
etc. Typically, inorganic (metals, ceramics, and glasses) and polymeric (synthetic and 
natural) materials have been used for such items as artificial heart-valves, (polymeric or 
carbon-based), synthetic blood-vessels, artificial hips (metallic or ceramic), medical 
adhesives, sutures, dental composites, and polymers for controlled slow drug delivery. 
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One area of intense research activity has been the use of polymers for controlled drug 
delivery. Among them, the biodegradable polymers which are broken down into 
biologically acceptable molecules that are metabolized and removed from the body via 
normal metabolic pathways have been widely used for sutures, controlled drug delivery 
and tissue engineering. During the last two decades, significant advances have been 
made in the development of biocompatible and biodegradable materials for biomedical 
applications (Sinha et al., 2004). 
 
5.2. Classification of Drug Delivery Systems 
 
Drug formulation researchs have focused on the systems that delay the release of 
drugs after their administration. For this reason, many drug delivery systems have been 
developed to achieve active and effective treatment. Table 5.1 summarizes the 
developed release systems, mostly used in the area of controlled drug delivery.  
 
Table 5.1. Classification of Drug Delivery Systems 
 
Drug delivery Systems Mechanisms 
Diffusion Controlled Systems Oral 
Matrix-type system 
Reservoir-type system 
Expandable system 
Floating system 
Transdermal 
Mucoadhesive system 
Inert matrix system 
Semisolid/reservoir matrix system 
Dissolution Controlled Systems Based on dissolution controlled release of;  
     solid particles 
     coated technologies 
     matrix technologies 
Osmotic Controlled Systems Osmotic delivery systems for solids; 
      Type I: single compartment 
      Type II: multiple compartments 
Osmotic delivery systems for liquids 
Biodegradable Polymeric Systems Microparticles 
Nanoparticles 
Implants 
Programmable Delivery Systems Pulsatile systems 
Feedback-controlled systems 
Stimulus Responsive Physically modulated: Temperature 
Chemically modulated: pH dependent 
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Among them, oral administration is the main way of delivering immediate 
release of drugs because of easy delivery, better acceptance by patients and cost 
effective manufacturing. After investigation of sustained release technology, different 
strategies and technologies have been developed with the view to achieve controlled 
drug release. The oral administration of therapeutics leads to internalization by the 
matrix at the mouth, stomach, small intestine and colon. Using drug delivery systems, it 
is possible to target these different tissue systems for local drug action within the 
gastrointestinal tract. Chitosan is one of the most widely used polymers in the 
gastrointestinal release systems (Patel and Amiji, 1996).  
Chitosan based delivery systems are advantageous because of its pH sensivity 
and mucoadhesive property. The fluctuation of pH through the gastrointestinal tract 
(GI) is significant, ranging from 1 to 7.5 (Gupta and Kumar, 2000). This offers 
significant drug release targeting based on pH shifts by regulating the swelling 
response. Mucoadhesion, the ability of a material to bind to the mucus lining of the GI 
tract, is regulated by the affinity of the drug delivery systems for the mucin 
glycoproteins of the mucus. Chitosan is very good mucoadhesives due to their non-toxic 
nature, and can be made to bind to mucins through either electrostatic or hydrophobic 
interactions. The amine and hydroxyl groups of it have been implicated in the chitosan's 
excellent mucoadhesive properties, leading to prolonged residence time in the 
gastrointestinal tract (Hejazi and Amiji, 2002). 
Unlike the harsh environment of the gastrointestinal tract, low-molecular weight 
drugs can be administered by local transdermal drug delivery systems, which benefit 
from sustained drug release and easy therapy interruption by removal of the drug 
delivery system. Hydrogels offer attractive drug delivery system structures because of 
their high water content, providing a comfortable feeling on the patient's skin, leading to 
better compliance over the duration of the therapy. 
Density determines the location of the matrix system in the stomach. Matrix with 
density lower than gastric contents can float to the surface, while high-density systems 
sink to bottom of the stomach. Gastric contents have a density close to water 1.004 g 
cm
-3 
(Bardonnet et al., 2006). A dense delivery system has been used for sinking of the 
matrix at the bottom of the stomach and so it significantly affects the gastric residence 
time. On the other hand, it floats when the density of the system is lower than of the 
stomach, and it remains buoyant in the stomach for a prolonged period of time, with a 
potential for continuous release of drug.  
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Among the drug delivery systems, the diffusion-controlled and the dissolution-
controlled ones have been widely used for delivering the drug. Chitosan can be 
effectively used to develop such systems because of its biodegradability and hydrophilic 
characters.  
 
5.3. Controlled-Release Mechanisms 
 
There are three primary mechanisms by which active agents can be released 
from a delivery system: diffusion, swelling followed by diffusion, and degradation. Any 
or all of these mechanisms may occur in a release system.  
Diffusion occurs when a drug or other active agent passes through the polymer 
that forms the controlled-release device. The diffusion can occur through pores in the 
polymer matrix or by passing between polymer chains. In Figure 5.1(a), a polymer and 
active agent have been mixed to form a homogeneous system, also referred to as a 
matrix system. Diffusion occurs when the drug passes from the polymer matrix into the 
external environment. As the release continues, its rate normally decreases with this 
type of system, since the active agent has a progressively longer distance to travel and 
therefore requires a longer diffusion time to release (Boateng et al., 2007). For the 
reservoir systems shown in Figures 5.1 (b) and (c), the drug delivery rate can remain 
fairly constant. In this design, a reservoir, solid drug, dilute solution, or highly 
concentrated drug solution within a polymer matrix, is surrounded by a film or 
membrane of a rate-controlling material. The only structure effectively limiting the 
release of the drug is the polymer layer surrounding the reservoir. Since this polymer 
coating is essentially uniform and constant thickness, the diffusion rate of the active 
agent can be kept fairly stable throughout the lifetime of the delivery system. In a 
transdermal drug delivery system, only one side of the device will actually be delivering 
the drug (Wang et al., 2005). 
Since the drug delivery device is stable in the biological environment and does 
not change its size either through swelling or degradation in diffusion-controlled 
systems, the combinations of polymer matrices and bioactive agents chosen must allow 
for the drug to diffuse through the pores or macromolecular structure of the polymer 
(Sinha et al., 2004). 
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Figure 5.1. (a) Drug delivery from matrix drug delivery system; (b), (c) Drug delivery 
from reservoir devices: implantable or oral systems and transdermal 
systems, respectively. 
 
Swelling-controlled release systems are initially dry and, when placed in the 
release media, body absorb water or other body fluids and swell. The swelling increases 
the aqueous solvent content within the formulation as well as the polymer mesh size, 
enabling the drug to diffuse through the swollen network into the external environment. 
Examples of reservoir and matrix systems are shown in Figures 5.2a and 5.2b, 
respectively. Most of the materials used in swelling-controlled release systems are 
based on hydrogels, which are polymers that swell without dissolving when placed in 
water or other biological fluids. 
 
Figure 5.2. Drug delivery from (a) reservoir and (b) matrix swelling-controlled release 
systems. 
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Depending upon the polymer, the environmental change can involve pH, 
temperature, or ionic strength, and the system can either shrink or swell upon a change 
in any of these environmental factors. A number of these environmentally sensitive or 
"intelligent" hydrogel materials are listed in Table 5.2. For most of these polymers, the 
structural changes are reversible and repeatable upon additional changes in the external 
environment. 
 
Table 5.2. Environmentally sensitive polymers for drug delivery  
(Source: Kim, 1996) 
 
Stimulus Hydrogel Mechanism 
pH 
Acidic or basic 
hydrogel 
Change in pH 
Swelling-release of drug 
Ionic strength Ionic hydrogel 
Change in ionic strength 
Change in concentration of ions inside gel 
Change in swelling-release of drug 
Chemical 
species 
Hydrogel containing 
electron-accepting 
groups 
Electron-donating compounds 
Formation of charge/transfer complex 
Change in swelling-release of drug 
Enzyme-
substrate 
Hydrogel containing 
immobilized enzymes 
Substrate present 
Enzymatic conversion 
Product changes swelling of gel-release 
of drug 
Magnetic 
Magnetic particles 
dispersed in alginate 
microshperes 
Applied magnetic field 
Change in pores in gel 
Change in swelling-release of drug 
Thermal 
Thermoresponsive 
hydrogel poly (N-
isopro- 
pylacrylamide) 
Change in temperature 
Change in polymer-polymer and water-
polymer interactions 
Change in swelling-release of drug 
Electrical 
Polyelectrolyte 
hydrogel 
Applied electric field 
Membrane charging 
Electrophoresis of charged drug 
Change in swelling-release of drug 
Ultrasound 
irradiation 
Ethylene-vinyl alcohol 
hydrogel 
Ultrasound irradiation 
Temperature increase-release of drug 
 
As an example, the pH sensitive materials are ideal for systems such as oral 
delivery, in which the drug is not released at low pH values in the stomach but rather at 
high pH values in the upper small intestine. 
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The third controlled drug delivery mechanism is achieved by using 
biodegradable polymers in the system. These materials degrade within the body, 
eliminating the need to remove a drug delivery system after release of the active agent 
has been completed. The most common formulation for these biodegradable materials is 
that of microparticles, which have been used in oral delivery systems and in 
subcutaneously injected delivery systems (Vasudev et al., 1997). 
 
5.4. Theory and Mathematical Models of the Controlled Release 
 
The concept of controlled release is to release a bioactive agent over a 
designated period of time at a particular rate. Controlled release devices most 
commonly utilize polymeric systems to control the release kinetics. Practical use of 
controlled drug release systems requires well-defined kinetic behavior that provides 
administration of a specific drug at an optimum level through release process. 
Many controlled-release products are designed on the principle of embedding 
the drug in a porous matrix. Release of active ingredients from encapsulates can be 
induced or triggered by various methods including diffusion, mechanical rapture, 
melting, dissolution, hydration, enzyme attack, chemical reaction, hydrolysis, 
disintegration and do forth. It is possible to classify the controlled release systems as 
(Kim, 1996); 
 Diffusion Controlled Systems – Diffusion of the drug through a 
polymer controls the release rate. 
            o Reservoir (Membrane) systems 
            o Monolithic (Matrix) systems 
 Swelling Controlled Systems – Swelling of the polymer, and 
subsequent diffusion of the drug through the polymer controls the release 
rate. 
 Chemically Controlled Systems – Hydrolytic or enzymatic cleavage 
results in polymer swelling, erosion, or release of covalently bonded 
drug by cleavage of a pendent chain. 
 Osmotically Controlled Systems – Osmotic forces control the release of 
drug. 
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 Dissolution Controlled Systems – Dissolution of the polymeric carrier 
results in release of drug. 
 Externally Controlled Systems – An external stimuli results in release 
of drug. 
            o Magnetically Controlled Systems 
            o Ultrasound Controlled Systems 
 Each system exhibits characteristic release properties depending on the 
physicochemical characteristics and structural conditions, which determine the resulting 
governing process.   
 A major challange in controlled release is to understand the complex interactions 
of various dynamic processes accompanying the mass transfer. Reservoir and matrix 
systems are commonly expected to be diffusion derived systems.  
Fick‟s law of diffusion can often be used to describe the transport of a bioactive 
agent through a diffusion controlled polymer system. Fick‟s law in one dimension can 
be represented by the following equation; 
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Fick‟s law has been the basis for all theoretical and experimental studies on 
diffusion transport. It states that the steady state diffusion flux, J (mol.m
-2
.s
-1
), is 
proportional to the concentration gradient (dCi/dx). D is the diffusivity of the bioactive 
agent.  
Fick's first law presents a steady state diffusional release and Fick's second law 
is used for the description of transient phenomena where the concentration profile of the 
drug in the polymer is not constant during diffusion. 
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Fick's models are adapted to passive diffusional systems where the diffusion 
coefficient (D) is assumed to be constant (no changes in the physicochemical properties 
of the polymer during the release). Such systems are called Fickian systems. 
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The considered geometry is important. For the spherical matrix, Fickian 
diffusion is commonly expressed in Equation 5.3. 
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Equation 5.3 shows the change in amount of substance released from spherical 
particles, where q represents amount of substance transferred through particle, r is 
distance from the center of the sphere and D is diffusion coefficient. This equation 
assumes constant diffusion coefficient and the case is valid at low concentrations 
considering the following initial and boundary conditions (Crank, 1975): 
 
at t=0, q=M 
                                                 for t>0 and at r=Rp, q=Mt                   (5.4) 
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Integrating Equation 5.3 with a given boundary conditions; 
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 Equation 5.5 is known as Crank equation, which is valid for the homogeneous 
spherical encapsulates under infinite sink condition. Mt is the material released from the 
encapsulate, M∞ is the initial loading, D is the effective diffusion coefficient of solute 
through the encapsulate matrix and Rp is the radius of the encapsulate. 
 Corresponding to early stage of release, the short term [ 3.0
M
M t ], solution 
of the Equation 5.5 (Crank, 1975) is; 
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For long term [ 7.0
M
M t ], Equation 5.5 is written as follows: 
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Equation 5.6 suggests a square root relation as shown in Equations 5.8 and 5.9; 
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K is a constant reflecting the design variables of the system. Thus, the fraction of 
drug released is proportional to the square root of time.  
Equation 5.7 might also be described as; 
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The term first order equation can be derived from the equation; 
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where n is the reaction order. Solving Equation 5.11 for n=1 gives the first order release 
equation.  
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which can also be integrated to obtain the following equation; 
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For zero-order equation, one assumes that the release is not dependent on its 
concentration and therefore n=0; 
 
                                                           ktMM t                                              (5.14) 
 
It should be noted that zero-order kinetic provides constant release of bioactive 
compounds with time. When the active ingredient loaded to an encapsulate system is 
over saturated, the release rate of encapsulated solute to an infinite sink environment 
becomes constant.  
In literature, Equation 5.9 is known as Higuchi equation. An important 
advantage of this equation is its simplicity. However, when applying it to controlled 
drug delivery systems, the assumptions should carefully be kept in mind: (i) the initial 
drug concentration in the system is much higher than the soluble amount of the drug at 
time t (which explained by the initial short time solution of the Crank equation), (ii) 
Mathematical anaysis is based on one-dimensional diffusion, (iii) Swelling or 
dissolution of the polymer carrier is negligible, (iv) The diffusivity of the drug is 
constant. 
It is evident that these assumptions are not valid for most controlled drug 
delivery systems. Generally encapsulates exhibit more complex release kinetics due to 
the interactions with other rate limiting steps, such as hydration, structural breakdown 
and chemical/or metabolic reactions. However, due to the extreme simplicity of the 
equation, it is often used to analyze experimental drug release data to get a rough idea of 
the underlying release mechanism.  
Figure 5.3 indicates the possible release profiles from the microcapsules. Burst 
release is typical for soluble or broken ones. Release might also be triggered after a 
certain period of time by, e.g. pH change or addition of enzymes. Zero-order release is 
obtained with over saturated amounts of active component in the core or with 
microcapsules where the thin shell is the rate limiting step. First or multiple order 
release is common for matrix type of encapsulates and release due to other interactions. 
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Figure 5.3. Release profiles from encapsulates. 
 
 A more comprehensive semiemprical equation to describe drug relase from 
polymeric systems is to so call power law: 
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Here, Mt and M∞ are the absolute cumulative amount of drug released at time t 
and infinite time, respectively; k is a constant incorporating structural and geometric 
characteristic of the device, and n is the release exponent, indicative of the mechanism 
of drug release (Siepmann and Peppas, 2001). 
Equation 5.9 represents the special case of the power law where n=0.5.  The 
power law or Peppas model can be seen as a generalization of the observation that 
superposition of two apparently independent mechanisms of drug transport, a Fickian 
diffusion and a case-II transport, describes in many cases dynamic swelling of and the 
type of coupling relaxation and diffusion. Case-II transport reflects the influence of 
polymer relaxation on molecules‟ movement in the matrix (Siepmann and Peppas, 
2001).  
Equation 5.15 has two special cases of n=0.5, which indicates diffusion 
controlled release; and n=1 (indicating swelling controlled drug release) for the release 
kinetics of bioactive compounds from the matrix having a slab geometry. For spheres 
and cylinders different values of n have been derived as listed in Table 5.3. 
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Table 5.3. Exponent n of the power law and drug release mechanism from polymeric 
controlled delivery systems of different geometry (Source: Siepmann and 
Peppas, 2001). 
 
Exponent, n 
Drug release 
mechanism 
Thin film Cylinder Sphere  
0.5 0.45 0.43 Fickian diffusion 
0.5<n<1 0.45<n<0.89 0.43<n<0.85 Anomalous 
transport 
1 0.89 0.85 Case-II transport 
 
 
Satojeni et al., (2010) developed a chitosan-albumin based microspheres 
including clarithromycin as a drug to provide prolonged contact time of drug delivery to 
treat stomach ulcer. Zero order, Higuchi and Peppas models were used to investigate the 
release kinetics. Both Higuchi and Peppas models were found to be best fitted in all 
dissolution profiles having a higher correlation coefficients and n value was determined 
around 0.5.  
Table 5.4 indicates the controlled release of clarithromycin from different 
polymer/-crosslinker matrix including the kinetic analysis.  
 
Table 5.4. Mathematical models applied to analyse kinetics of the release. 
 
Polymer-crosslinker Drug Target 
Models 
used 
References 
Chitosan-albumin Clarithromycin 
Stomach 
ulcers 
Zero-order, 
Higuchi 
and Peppas 
Satojeni et 
al., 2010. 
Gellan gums Clarithromycin 
Stomach 
specific 
delivery 
Zero- 
order, 
First-order, 
Higuchi 
Rajinikanth 
and Mishra, 
2009. 
Chitosan-
ethylcellulose-
paraffin 
Clarithromycin 
H. pylori 
 
Zero-order, 
First order, 
Higuchi 
and Peppas 
Rajinikanth 
et al., 2008. 
Chitosan-Carboxy- 
methylcellulose 
tablet 
Clarithromycin H.pylori 
Zero- 
order, 
Peppas 
Burgaz et al., 
2008. 
Hydroxypropyl 
methyl cellulose 
Different drugs  
Higuchi 
and Peppas 
Siepmann 
and Peppas, 
2001. 
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Rajinikanth and Mishra (2009) used gellan gums to obtain floating beads 
ontaining clarithromycin using iontotropic gelation method. They concluded that by 
kinetic treatment of the in vitro drug release data with different kinetic equations 
revealed matrix diffusion mechanism. In another study, chitosan and 
carboxymethylcellulose sodium interpolymer complexes were formed for controlled 
release of clarithromycin (Burgaz et al., 2008).  They indicated that, release rate was 
explained by Fickian and dependent on pH and on polymer proportion. Siepmann and 
Peppas (2001) on the other hand, developed a mathematical models to predict the 
release rate kinetics of a drug from hydroxypropyl methylcellulose based 
pharmaceutical devices. Classical Higuchi equation and the so-called power law, as well 
as more complex mechanistic theories that consider diffusion, swelling and dissolution 
processes simultaneously are presented.   
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CHAPTER 6 
 
MATERIALS AND METHODS 
 
6.1. Materials 
 
High molecular weight chitosan (Sigma-Aldrich Chemie, Germany, cat. # 
419419, deacetylation degree %86) was used in the microsphere manufacturing. 
Clarithromycin was supplied by Ranbaxy Pharmaceuticals Inc. Cinnamon bark oil, 
clove oil, thyme oil, lemongrass oil and lemon oil were purchased from Sigma 
Chemical Co. Genipin was purchased from Challenge Bioproducts Co., Ltd. HPLC grade 
ethanol and methanol were used as a solvent to dissolve clarithromycin and essential 
oils. Acetic acid and acetonitrile was purchased from Merck, Darmstadt. Phosphate 
buffered saline (PBS) solution (pH=7.3) was obtained by dissolving PBS tablet in 100 
ml deionized water. Simulated gastric fluid (SGF) was prepared by mixing pepsin (3 
g/l) and NaCl (0.5 %) and it was adjusted to pH 3 and pH 5 with HCl. Sodium acetate 
and acetic acid were used in the preparation of buffer solutions with a pH range of 3-7. 
All buffer solutions were stored at 4 °C until use up to 7 days. Mueller Hinton Agar 
(Oxoid) and defibrinated sheep blood (Oxoid) were used in the antimicrobial 
susceptibility testing. 
 
6.2. Methods 
 
6.2.1. Minimum Inhibitory Concentration (MIC) Determination by 
Agar Dilution Method 
 
The standard strain of Helicobacter pylori NCTC 11637 (cagA, vacA, oipA, 
babA (+)) was used in the study. H. pylori was identified according to colony 
morphology, Gram staining, microaerophilic growth (at 37°C), and the production of 
oxidase, catalase and urease. Antimicrobial susceptibility tests were performed 
according to performance standards for antimicrobial susceptibility testing of Clinical 
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and Laboratory Standards Institute (CLSI, 2007). Minimum inhibitory concentrations 
(MICs), the lowest concentration of an antimicrobial that inhibits the growth of a 
microorganism, were determined using the agar dilution method. 
 
6.2.1.1. H. pylori Culture Media Preparation 
 
%7 Horse Blood Supplemented H. pylori Selective Medium 
 
19.5 gr Columbia Blood agar (Oxoid) was dissolved in 465 ml. distilled water 
and autoclaved at 121°C for 15 min. Then 35 ml of sterile Defibrinated Horse Blood 
(Oxoid) and 2 ml of Helicobacter pylori Selective Supplement (DENT, Oxoid) in 
sterile distilled water were added to the sterile agar solution at 50°C. 20 ml of culture 
medium was poured into each of 90 mm petri dishes. Agar plates were kept in 
incubator at 37°C for 24 h for contamination control. 
 
H. pylori Stock Culture Medium with 20% Glycerol 
 
Glycerol solution (40 %) (Baked Analyzed) and 40 ml of Brain Heart Infusion 
Broth (BHI) (Beckton Dickinson and Company) were autoclaved at 121°C for 15 min 
seperately. 10 ml of fresh human serum was added to medium kept at +4°C as 1 ml in 
sterile eppendorf tubes. 
 
6.2.1.2. H. pylori Culture Protocol 
 
Helicobacter pylori NCTC 11637 (cagA, vacA, oipA, babA (+)) standard strain 
was inoculated onto %7 Horse Blood Supplemented Columbia Blood agar (Oxoid) and 
incubated at 37°C for 3 days in microaerophilic environment in an anaerobic jar 
(Oxoid) with GasPak Campy Container System (Becton Dickinson and Company). H. 
pylori was identified according to colony morphology, Gram staining, microaerophilic 
growth (at 37°C), and the production of oxidase, catalase and urease. The subculture 
was obtained from the growing colonies on %7 Horse Blood Supplemented Columbia 
Blood agar. Colonies collected from subculture was kept at -80°C in a BHI Broth with 
%20 glycerol. 
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6.2.1.3. MIC Determination by Agar Dilution Method 
 
Preparation of Stock Clarithromycin Solution 
 
Clarithromycin solution was prepared by dissolving 25 mg clarithromycin 
in 25 ml methanol. 9 ml of PBS was added into 1 ml of clarithromycin solution 
and the stock solution was obtained as 100 µg/ml (w/v). The stock solution was 
sterilized with 0.22 µm sterile syringe filter and 2-fold serial dilutions were made 
in PBS resulting the clarithromycin concentration in the range of 50– 1.75 µg/ml. 
These concentrations were in the range of 1000 to 1 µg/ml when each of dilution 
was added into 50 ml growth medium. 
 
Preparation of Stock Essential Oil Solutions 
 
Lemongrass, cinnamon bark, clove leaf, lemon and thyme essential oils stock 
solutions were prepared by dissolving them in ethanol. 300 mg essential oil (Sigma) 
was dissolved in 3 ml ethanol. Stock solution as 100 mg/ml (w/v) was sterilized with 
0.22 µm sterile syringe filter and 2-fold serial dilutions were made in PBS resulting the 
essential oil concentration in tubes in the range of 50 mg/ml–50 µg/ml. These 
concentrations were in the range of 1000 to 1 µg/ml when each of dilution was added 
into 50 ml growth medium. 
 
Preparation of H. pylori Growth Medium 
 
5% sheep blood supplemented Mueller Hinton Agar (Oxoid) was used as 
growth medium. 1.9 g Mueller Hinton agar was dissolved in 46.5 ml distilled water and 
autoclaved at 121°C for 15 min. For each dilution of antibiotic or essential oil from 
serial dilutions, 2.5 ml steril Defibrinated Sheep Blood (Oxoid) and 1 ml of that 
dilution were added into agar. Each of 50 ml growth medium was poured onto 90 mm 
steril petri dishes as two equal amounts (25 ml). 1 ml PBS was addded into growth 
medium instead of drug solution in control plates.   
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Preparation of Bacterial Suspension 
 
H. pylori were harvested in 5 ml Brucella Broth and the number of bacteria was 
adjusted to McFarland 2 (6x10
8
 CFU/ml). (Clinical and Laboratory Standards Institute, 
2007). Turbidity of suspension was measured by Densimat (Biomerieux) 
 
Inoculation of Bacterial Suspension 
 
3 l of bacterial suspension adjusted to McFarland 2 was dropped onto growth 
medium which was Mueller Hinton Agar supplemented with 5 % defibrinated sheep 
blood and containing 1 to 0.0037 µg/ml of clarithromycin and of essential oil. 
Inoculated plates were incubated in a microaerophilic atmosphere (85% N2, 10% CO2, 
5% O2) with a GasPak Campy Container System (Becton Dickinson and Company) at 
37 °C for 96 h. After incubation the colony formation was visualized. The MIC was 
defined as the lowest concentration at which no visible growth was observed. 
 
6.2.2. Determination of Composition and Antioxidant Activities of 
Essential Oils 
 
The composition of essentil oils was determined by Gas Chromatography-Mass 
Spectrometry analysis. Chromatographic analysis was performed with an Agilent 6890 
Network GC system equipped with a mass spectrometric detector (Agilent 5973 
Network MSD). The separation was achieved on a HP-5MS (5% 
phenyl/methylsiloxane) (Capillary; 30 m x 0.25 mm x 0.25 μm) capillary column. 
Helium was used as carrier gas at a flow rate of 1 ml/min. 1 μl of samples were injected 
to a splitless injector that was maintained at 250 °C. The column temperature program 
was given in Table 1. 
 
Table 6.1. GC-MS temperature program for determination of essential oil composition 
 
Temperature (°C) Increase rate (°C/min) Hold Time (min) Total Time (min) 
40 °C --- 3 3 
150 °C 2 --- 58 
230 °C 8 3 71 
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The antioxidant activities of essential oils were determined by TEAC (Trolox 
Equivalent Antioxidant Capacity) method (Altiok et al., 2007). In this method, ABTS 
was dissolved in water to a 7 mM concentration and reacted with 2.45 mM potassium 
persulfate solution to form ABTS
+
. The mixture was kept in the dark at ambient 
temperature for 12-16 hours in order to complete the reaction. The absorbance of 
ABTS
+ 
solution was adjusted to 0.7 at 734 nm by diluting with ethanol. In the 
antioxidant capacity analysis, different amounts of essential oils were added into 3ml of 
ABTS
+ 
solution and the absorbance was measured at each 1 minute during 6 minutes at 
734 nm by Perkin Elmer UV-Visible spectrophotometer. The antioxidant activities of 
the samples by using ABTS
+
 were determined based on the antioxidant activity of 
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) solution and the 
results were given as the Trolox Equivalent Antioxidant Capacity (TEAC). The 
antioxidant capacity was calculated from the ratio of percentage inhibition (%) vs 
concentration graphs slopes of essential oil and trolox as ml essential oil / mmol trolox. 
This value was recorded as TEAC value (Altiok et al., 2007). 
 
6.2.3. Production of Clarithromycin and Cinnamon Bark Oil Loaded 
Chitosan Microspheres 
 
Chitosan microspheres were produced by spray dryer using Buchi® Mini Spray 
Dryer B-290 (Switzerland) with a 0.5 mm standard nozzle and a parallel flow. In the 
spray drying process, the filtered air is heated to a drying temperature and fed into the 
drying chamber. Feed solution is pumped to the atomizer. Drying air and sprayed feed 
solution move in a parallel flow. When the atomized droplets contact with hot air, 
evaporation occurs and dried products coming from cyclone are collected in the vessel. 
1 % (w/v) chitosan solution was prepared by dissolving chitosan in 2 % acetic 
acid and control microspheres were obtained by drying this solution at 140 °C in a spray 
dryer. Clarithromycin and chitosan solutions prepared by dissolving them in separate 
beakers were mixed and stirred for 1 h. The final concentrations of clarithromycin and 
chitosan in this solution were 0.1% and 1% (w/v), respectively. Clarithromycin loaded 
chitosan microspheres were obtained by drying this solution in a spray dryer at an inlet 
air temperature of 180°C and a feed rate of 4 ml/min. In order to produce the cinnamon 
bark oil loded chitosan microspheres, 2.5 ml of cinnamon bark oil was added 
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dropwisely into 500 ml of 1% chitosan solution prepared by dissolving chitosan in 2% 
acetic acid and stirred for 1 h. This solution was pumped to the atomizer at 6 ml/min 
feed rate and dried at inlet air temperature of 195°C. 
 
6.2.4. Optimization of the Production of Clarithromycin and 
Cinnamon Bark Oil Loaded Chitosan Microspheres 
 
Optimization of the spray drying process could be very important phenomenon 
in terms of product quality and process efficiency in the development of clarithromycin 
and cinnamon bark oil loaded chitosan microspheres. Since the particle size distribution, 
shape and surface properties, water activity and the spray drying efficiency are 
governed by the inlet air temperature, feed rate and clarithromycin or cinnamon bark oil 
concentration of feed solution, the significance of these variables, as well as interactions 
between them, were examined using a central composite design and response surface 
methodology (RSM). 
 Water activity of the spray dried microspheres was measured by HygroLab 3 
(Rotronic). The particle size distribution, shape and surface properties were examined 
by scanning electron microscope (Philips XL 30S FEG, FEI Company, Eindhoven, 
Netherlands). Spray drying efficiency (SE) was calculated to measure how much of 
microspheres were obtained after the manufacturing process as in Eqn (6.1); 
 
                          
  100
...
....
% 
polymerinitialofamount
esmicrospherdriedsprayofamount
SE                     (6.1) 
 
 Three factors as process inputs were the drying air temperature, solution feed 
rate and clarithromycin or cinnamon bark oil concentration of solution. The response 
variables were the moisture content, particle size distribution and surface morphology 
and spray drying efficiency. The levels of the factors were coded as -1 and +1, 
corresponding to the low and high levels respectively. Αlpha was taken as 1.68. Actual 
values are 170°C-190°C and 185°C-195°C for drying air temperature; 8-10 ml/min and 
6-10 ml/min for solution feed rate and 0.2%-0.6% (w/v) and 0.7%-1.3% (w/v) for 
clarithromycin or cinnamon bark oil concentration of the solutions, respectively. All 
statistical analyses were performed by MINITAB Statistical Software, Release 15. 
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6.2.5. Crosslinking of Microspheres by Genipin 
 
Microspheres were crosslinked by using genipin as a natural crosslinking agent for 
the clarithromycin and cinnamon bark oil loaded microspheres. The required amount of 
clarithromycin or cinnamon bark oil was added to the chitosan solution and stirred for 1h. 
20 ml genipin solution was added to the 300 ml chitosan solution in different concentrations 
(1-5 mM) and the resulting mixture was incubated at 50 ºC with magnetic stirring during 
different time periods (1-18 h). The effects of genipin concentration and crosslinking time 
on release kinetics were investigated. Chitosan-genipin-drug solutions were spray-dried 
under optimum spray drying conditions. Briefly, spray drying conditions were inlet 
temperatures of 170 ºC for clarithromycin and 195 ºC for cinnamon bark oil and sample 
flow rate of 6 mL/min.  
 
6.2.6. Characterization of Microspheres 
 
The size and the surface morphology of spray dried particles were investigated 
by scanning electron microscope (Philips XL 30S FEG, FEI Company, Eindhoven, 
Netherlands) in Center for Materials Research in Izmir Institute of Technology, Izmir, 
Turkey. The powders were fixed on a brass stub using double-sided adhesive tape and 
then were made electrically conductive by coating, in a vacuum, with a thin layer of 
gold for 60 sec. 
The zeta potential of clarithromycin, genipin and all formulations of 
microspheres was determined using a Malvern Zetasizer 3000 HSA (Malvern 
Instruments). All measurements were performed at 25°C in phosphate buffer of pH 5 
and repeated in triplicate. 
  The thermal properties of microspheres were analyzed by Thermogravimetric 
Analysis (TGA) (Shimadzu TGA-51) under N2 gas flow (40 ml/dak). In TGA analysis, 
the temperature was increased from 20C to 400C with heating rate of 10oC /min. The 
thermal properties of cinnamon bark oil were analyzed by Differential Scanning 
Calorimeter (DSC) in the temperature range of -20C -400C.   
The chemical structures of clarithromycin, chitosan and clarithromycin loaded 
microspheres were investigated by Nuclear Magnetic Resonance Spectrometry (Varian 
400 MHz) analysis (
1
H-NMR) by dissolving the samples in deuterium oxide (D2O). 
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  The swelling and degradation properties of microspheres in phosphate buffer of 
pH 5 were analysed by phase contrast microscope 
 
6.2.7. Clarithromycin Stability in Different pH Solutions 
 
Clarithromycin was dissolved in 2% acetic acid and incorporated into SGF 
with/without pepsin of pH 2.0 or 3.0 and phosphate buffer of pH 5.0 or 7.0. The 
degradation percentages of clarithromycin at different times in the medium were 
evaluated from the main peak area by HPLC assay. HPLC system working conditions 
and properties were given in Table 6.2. 
 
Table 6.2. The properties and operating conditions of HPLC system for clarithromycin 
 
Properties Specifications 
Column  Licrosphere C18 Reverse Phase Column 
Column length 250 mm 
Column diameter 4 mm 
Particle size 5 μm 
Mobile phase A: acetonitrile ; B: phosphate Buffer (pH 4.4) 
Flow rate 1.1 ml min
-1
 
Wavelength 205 nm 
Temperature 40 
o
C 
Detector Diode Array Detector 
Elution type Gradient elution 
 
 
6.2.8. Release of Clarithromycin and Cinnamon Bark Oil from 
Microspheres  
 
The release of clarithromycin and cinnamon bark oil from microspheres in 
phosphate buffer solution at pH 5 was performed in a thermoshaker at 37°C and 150 
rpm. 50 mg of microspheres were added into 20 ml buffer solution. 250 µl of sample 
was taken at different times and filtered from 0.45µm syringe filter. 250 µl of fresh 
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buffer solution was added to the release media after each sampling. Filtered sample was 
injected to HPLC. The calibration curve was obtained from different concentrations of 
clarithromycin solution.  
 Amount of cinnamon bark oil released from microspheres to phosphate buffer 
solution of pH 5 was determined by UV-Visible Spectrophotometer (Thermo Multiskan 
Spectrum). The most suitable wavelenght was 288 nm according to spectrum scanning. 
The calibration curve was obtained by different dilutions of cinnamon bark oil in 
ethanol.  
 
6.2.9. The Effects of Clarithromycin and Cinnamon Bark Oil Released 
from Microspheres on H. pylori  
 
 In order to determine the antibacterial activity of clarithromycin and cinnamon 
bark oil released from microspheres, the microspheres were incorporated in H. pylori 
inoculated growth medium.  
 The growth medium was prepared by dissolving 1.8 gr of Brucella Broth 
(Beckton Dickinson, BD) in 95 ml of distilled water and test tubes each having 10 ml of 
this solution was autoclaved at 121°C for 15 min. When the Brucella Broth was cooled 
to 50°C, 0.5 ml of fetal bovine serum (FBS) (Biochrom AG), sterilized by 0.22 µm 
syringe filter (Sartorius Stedim), was added to each broth. Broths was incubated at 
37°C for 24 h for contamination control and kept at +4 °C. 
 H. pylori NCTC 11637 standard strain cultured on 7% horse blood 
supplemented Columbia Blood Agar was inoculated into 40 ml broth having 5% FBS 
adjusted to McFarland 2 (6x10
8 
CFU/ml). 
In order to determine the antibacterial activity of control chitosan microspheres, 
0.0022 g of control chitosan microspheres, sterilized under UV light for 30 min., were 
added into bacterial suspension of 40 ml 5% FBS incorporated Brucella Broth adjusted 
to McFarland 2. The suspension was incubated under magnetic stirring in an anaerobic 
jar (Oxoid) containing GasPak Campy Container System (Becton Dickinson and 
Company) at 37°C in a microaerophilic environment. 100 µl of sample was taken from 
the suspension at 0, 8, 24, 32 and 48 h of incubation and then 10
-1
, 10
-2
, 10
-3
, 10
-4
, 10
-5
, 
10
-6
, 10
-7
, 10
-8
 and 10
-9
 serial dilutions were prepared in steril eppendorf tubes having 
900 µl of 5% FBS incorporated Brucella Broth. 100 µl sample taken from 10-4, 10-5,    
 65 
10
-6
, 10
-7
, 10
-8
 and 10
-9
 dilutions was inoculated onto 7% horse blood supplemented 
Columbia Blood Agar in an anaerobic jar (Oxoid) containing GasPak Campy Container 
System (Becton Dickinson and Company) at 37°C in a microaerophilic environment for 
3 days. 
Similarly, 0.0022 g of clarithromycin loaded uncrosslinked and genipin 
crosslinked chitosan microspheres , sterilized under UV light for 30 min., were added 
into bacterial suspension of 40 ml 5% FBS incorporated Brucella Broth adjusted to 
McFarland 2 in order to determine the antibacterial activity of clarithromycin loaded 
chitosan microspheres (approximately 1µg/ml clarithromycin in solution after complete 
release). The remaining procedure was the same with that of control microspheres. 
In order to determine the antibacterial activity of cinnamon bark oil loaded 
chitosan microspheres, 0.022 g of control chitosan microspheres, sterilized under UV 
light for 30 min., were added into bacterial suspension of 40 ml 5% FBS incorporated 
Brucella Broth adjusted to McFarland 2 (approximately 4.6 µg/ml cinnamon bark oil in 
solution after complete release). The remaining procedure was the same with that of 
control microspheres. 
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CHAPTER 7 
 
RESULTS AND DISCUSSIONS 
 
7.1. Minimum Inhibitory Concentration (MIC) Study 
 
In the inhibition test by agar dilution method, the minimum clarithromycin 
concentration inhibiting H. pylori growth was observed as 0.125 µg/ml. This result was 
also proved by catalase, oxidase, urease test and Gram staining. Similarly, Vega et al. 
determined the MIC of clarithromycin on H. pylori NCTC 11638 standard strain as 
0.125 µg/ml (Vega et al., 2009). The MIC of clarithromycin on H. pylori NCTC 11637 
standard strain was determined as 0.12 µg/ml (Ustun et al., 2006).  
The MIC values of lemongrass, cinnamon bark, clove leaf, lemon and thyme 
essential oils against H. pylori were determined as 62, 8, 125, 500 and 62 µg/ml, 
respectively. Bergonzelli et al. determined the MBC‟s (minimum bactericidal 
concentration) of cinnamon bark oil, lemongrass oil and thyme oil as 40 µg/ml and that 
of clove oil as 100 µg/ml. It was also expressed that the climate, soil type and age of 
plant affect the quality, amount and composition of essential oil resulting different 
antibacterial properties depending on the origin of the essential oil. So, determining the 
antibacterial effects of the components of essential oils could be more reliable and 
comparable (Bergonzelli et al., 2003).  
As a result of the inhibition tests, cinnamon bark oil was the most effective 
essential oil on H. pylori. Therefore, in the following studies cinnamon bark oil loaded 
chitosan microspheres were only produced, characterized and the release experiments 
were carried out. 
 
7.2. Composition and Antioxidant Activities of Essential Oils 
 
The chemical and percentage composition of five essential oils used in this study 
was given in Table 3. The main components of lemongrass oil, cinnamon bark oil, 
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lemon oil, thyme oil and clove leaf oil were found as citral (58%), cinnamaldehyde 
(72%), limonen (65%), carvacrol (69%) and eugenol (82%), respectively.  
Table 7.1. Chemical and percentage composition of essential oils 
# Chemical Compounds 
Cinnamon 
Bark oil 
Clove 
Leaf oil 
Lemon 
oil 
Lemongrass 
oil 
Thyme 
oil 
1 (-) Borneol     1.91 
2 (-)-Camphor     0.20 
3 (-)-Spathullenol     0.12 
4 (+)-a-Terpineol     0.48 
5 
1,8-Cineole 
(Eucalyptol) 0.18     
6 
1-Metoxy-4-methyl-2- 
(1-methylethyl)-
benzene     
0.57 
7 4-Terpineol     1.47 
8 4-Thujanol 0.10    0.45 
9 a-bergamotene   0.36   
10 a-Caryophylene 0.82 1.60  0.13 0.18 
11 a-citral    58.39  
12 a-lemonene  0.09 65.42   
13 a-Phellandrene 0.86  0.52  0.15 
14 a-Pinene 0.66  2.39  0.30 
15 a-Terpinene   0.25   
16 a-Terpineol 0.40  0.13   
17 a-Thujene 0.17     
18 b-Bisabolene   0.47  1.34 
19 b-Caryophylene 4.16 14.73 0.21 0.88 1.35 
20 b-citral   0.54 37.75  
21 Benzaldehyde 0.29     
22 Benzene propanal 0.23     
23 Benzyl benzoate 1.05     
24 b-Linalool 2.86    2.35 
25 b-Myrcene   1.09   
26 b-Pinene 0.31  13.97  0.29 
27 b-Thujene 2.36    0.05 
28 Camphene 0.28  0.08  0.18 
29 Carvacrol     68.96 
30 Caryophylene oxide 0.76 0.31   0.19 
31 Champore 0.12     
32 Cinnamyl acetate 3.72     
33 Cinnamyl alcohol 0.12     
34 Cis-Cinnamaldehyde 0.32     
35 cis-verbenol    0.88  
36 citral   0.91   
 
(Cont. on next page) 
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Table 7.1. (cont.) 
 
# Chemical Compounds 
Cinnamon 
Bark oil 
Clove 
Leaf oil 
Lemon 
oil 
Lemongrass 
oil 
Thyme 
oil 
37 Copaene 0.71 0.42    
38 Eucalyptol (cineole)     0.85 
39 Eugenol 3.87 82.41    
40 Methylthymilether     0.15 
41 Nerol    0.94  
42 nerol acetate   0.34 0.62  
43 
o-Methoxy 
cinnamaldehyde 
0.41  
   
44 p-a-Dimethylcityrene     0.42 
45 p-Cymene 2.53  0.65  8.40 
46 p-Terpinene     0.72 
47 sabinene   1.57   
48 Safrene 0.16     
49 sigma-cadinene  0.29   0.18 
50 Terpinene-4-ol 0.19     
51 Terpinolene 0.35  0.42  0.65 
52 teta-terpinene   10.10   
53 Thymol     7.75 
54 trans-Cinnamaldehyde 71.69     
 
 
The antioxidant activity of essential oils was calculated from the ratio of 
percentage inhibition (%) vs concentration graph slopes (Figure 7.1) of essential oil and 
trolox. This value was recorded as TEAC value and tabulated in Table 7.2. 
 
 69 
 
 
  
  
 
 
Figure 7.1. Lemongrass oil (a), cinnamon bark oil (b), lemon oil (c), thyme oil (d), clove leaf oil (e) and trolox (f) percentage inhibition graphs. 
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Table 7.2. The trolox equivalent antioxidant capacities (TEAC) of essential oils 
 
Essential oil TEAC 
(ml essential oil/mmol trolox) 
lemongrass oil 0.61 
cinnamon bark oil 67.95 
lemon oil 0.24 
thyme oil 54.14 
clove leaf oil 1484.41 
 
 
The highest antioxidant activity was observed in clove leaf oil. This activity may 
be due to its major component, eugenol. Moreover, cinnamon bark oil and thyme oil 
also have very high antioxidant activities probably due to cinnemaldehyde and 
carvacrol, respectively. These natural antioxidants may thus serve as novel therapeutic 
tools in alleviating H. pylori-induced oxidative damage. 
 
7.3. Optimization of the Production of Clarithromycin and Cinnamon 
Bark Oil Loaded Chitosan Microspheres 
 
Spray drying of chitosan solutions having 0.2-0.6% (w/v) and 0.7%-1.3% (w/v) 
clarithromycin and cinnamon bark oil concentrations, respectively, was carried out in 
the specified drying air temperatures and feeding rates.  The synthesized particles were 
graded in four categories (Table 7.3) according to their shapes (wrinkled or smooth) and 
particle size distributions (monodisperse or polydisperse) which indicate the adequacy 
grade of the particles for the specific use. The surface properties, particle size and shape 
are very important for the practicability of the particles.The particle size in the range of 
1-5 μm is expected to have good aerodynamic properties that brings also the tendency 
of small particles to agglomerate due to the Van der Waals forces. The stickness of a 
particle is related to the moisture content. Moisture content represents a measure of the 
quantity of water in a product. It provides information about yield, quantity and texture 
of product. A portion of the total water content present in a product is strongly bound to 
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specific sites on the chemicals that comprise the product. These sites may include the 
hydroxyl groups of polysaccharides, the carbonyl and amino groups of proteins, and 
other polar sites. Hydrogen bonds, ion-dipole bonds, other strong chemical bonds 
tightly bound water. Some water is bound less tightly, but is still not available. Water 
activity is a measure of how efficiently the water present can take part in a chemical 
reaction.  It is defined as “free” or “unbound” water in a system and determined as the 
vapor pressure of water in a sample divided by the vapor pressure of pure water at the 
sample temperature (Beristain et al., 2002). Water activity affects the surface charge and 
stickiness of the particles. It provides valuable information about microbial spoilage, 
chemical stability and physical stability. Besides particle size, shape and moisture 
content, spray drying efficiency is also a important parameter in a spray drying process.  
Spray drying is a solvent evaporation process. The solvent in the droplets is removed 
very quickly due to heat energy provided in the spray dryer. The maximum spray drying 
efficiency can be achieved from a balance of the amount of heat energy input and the 
amount of heat energy used in the evaporation process which is related to the amount of 
the sample input. 
Several factors were hypothesized to see the effects on the properties of drug 
loaded chitosan microspheres. The properties of the synthesized microspheres that were 
monitored were “water activity”, “particle type” and “spray drying efficiency”. 
Statistical analysis based on a central composite design was performed to examine the 
influence of the three variables ( inlet air temperature, drug concentration and feed flow 
rate) on the final properties of clarithromycin and cinnamon bark oil loaded chitosan 
microspheres.  These variables were examined at three levels: upper, medium and lower 
limits.  
 
Table 7.3. Categorization of spray dried particles 
 
Type 1 smooth, 1-5 micron, monodisperse 
Type 2 smooth, 1-5 micron, polydisperse 
Type 3 Wrinkled, 1-5 micron, polydisperse 
Type 4 sticky, 1-5 micron, polydisperse 
 
 
Table 7.4 lists the results of the experiments performed according to the 
experimental design for the production of clarithromycin loaded microspheres. The 
analysis was done using coded units. 
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Table 7.4. The results of experiments performed according to statistical design for the 
production of clarithromycin loaded microspheres. 
 
Run 
Number 
Inlet Air 
Temperature 
(A) 
Feed 
Rate 
(B) 
Clarithromycin 
Concenration 
(C) 
Water Activity 
aw 
Particle 
Type 
Efficiency 
(%) 
1 -1 -1 -1 0.262 2 58.87 
2 1 -1 -1 0.260 3 47.18 
3 -1 1 -1 0.476 2 46.49 
4 1 1 -1 0.922 4 34.59 
5 -1 -1 1 0.483 2 65.40 
6 1 -1 1 0.414 2 62.29 
7 -1 1 1 0.524 4 47.84 
8 1 1 1 0.675 4 61.92 
9 -1.68 0 0 0.652 1 58.76 
10 1.68 0 0 0.659 2 42.71 
11 0 -1.68 0 0.320 1 52.54 
12 0 1.68 0 0.281 4 14.19 
13 0 0 -1.68 0.429 2 53.48 
14 0 0 1.68 0.652 4 58.95 
15 0 0 0 0.410 2 51.57 
16 0 0 0 0.412 2 51.41 
17 0 0 0 0.408 2 52.58 
 
 
The estimated regression coefficients for water activity of clarithromycin loaded 
microspheres were given in Table 7.5.  
 
Table 7.5. Estimated regression coefficients for water activity of clarithromycin loaded 
microspheres 
 
Term        Coef    SE Coef    T      P 
Constant  25.0882    2.957   8.484  0.000 
A          1.4029    1.389   1.010  0.346 
B          4.8760    1.389   3.511  0.010 * 
C         -1.5344    1.389  -1.105  0.306 
A*A        0.6684    1.529   0.437  0.675 
B*B        0.2265    1.529   0.148  0.886 
C*C       -1.1877    1.529  -0.777  0.463 
A*B        4.5000    1.814   2.480  0.042 * 
A*C       -4.0000    1.814  -2.204  0.063 
B*C       -5.2500    1.814  -2.893  0.023 * 
 
* The terms with P value less than or equal to 0.05 have been considered as significant. 
 
 
The regression equation (Equation 7.1) for water activity was as follows, with a 
regression coefficient R
2
 of 83.37 %: 
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                                   322111
25.55.4876.4088.25ˆ xxxxxy                (7.1) 
 
Coefficient estimates and the p-values verified the significance of the main 
factor of inlet air temperature, second order interactions of inlet air temperature and feed 
rate and clarithromycin concentration and feed rate. The inlet air temperature was found 
to be the most effective parameter on water activity. Feed rate alone was not an 
effective parameter, but the interactions with inlet air temperature and concentration 
indicated significance.  
Morphology of clarithromycin loaded microspheres was investigated by 
scanning electron microscopy to decide particle classifications according to Table 7.3. 
Mostly, all particles were smooth and uniformly distributed in the size range of 1-5 μm. 
(Figure 7.2). However, more sticky particles with low sphericity were also observed due 
to the insufficient drying. The micrographs depicted different particle shaped and sized 
microspheres, obtained at each run are given in Figure A.1 in Appendix A.  
 
Run 
No 
5000x 10000x 
 
 
 
 
 
10 
 
 
 
  
 
Figure 7.2. SEM micrographs of clarithromycin loaded microspheres manufactured by 
spray drying according to central composite design; run number: 10. 
 
 
The estimated regression coefficients for particle type of clarithromycin loaded 
microspheres were given in Table 7.6.  
 
 
 
 75 
Table 7.6. Estimated regression coefficients for particle type of clarithromycin loaded 
microspheres 
 
Term           Coef   SE Coef        T       P 
Constant    1.96639    0.3063    6.419   0.000 
A          0.34282    0.1439    2.383   0.049 * 
B           0.73556    0.1439    5.113   0.001 * 
C           0.31952   0.1439    2.221   0.062 
A*A        -0.06101    0.1583   -0.385   0.711 
B*B         0.29254    0.1583    1.848   0.107 
C*C         0.46932    0.1583    2.964   0.021 * 
A*B         0.12500    0.1880    0.665   0.527  
A*C        -0.37500    0.1880   -1.995   0.086  
B*C         0.37500    0.1880    1.995   0.086  
* The terms with P value less than or equal to 0.05 have been considered as significant. 
 
 
The regression equation (Equation 7.2) for particle type was as follows, with a 
regression coefficient R
2
 of 89.15 %: 
 
                                    
2
3212 469.0736.0343.0966.1ˆ xxxy                     (7.2) 
 
This equation revealed that the key parameters that had dominant effect on 
particle type of microspheres as inlet air temperature, feed rate, and pure quadratic term 
(Table 7.6). 
In spray drying, it was observed that some of the liquid droplets were attached 
inside the wall of the main chamber. Once the inlet air temperature was set below 
170°C, or the pump rate was chosen to be faster than 8 ml/min, the solvent in the 
droplets could not be fully evaporated and the spray drying efficiency was calculated 
below 50%. 
The estimated regression coefficients for drying efficiency of clarithromycin 
loaded microspheres were given in Table 7.7.  
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Table 7.7. Estimated regression coefficients for the efficiency of clarithromycin loaded 
microspheres 
 
Term         Coef   SE Coef       T         P 
Constant   51.4277     4.382   11.737   0.000 
A          -2.8988     2.058   -1.409   0.202 
B          -7.8651     2.058   -3.822   0.007 * 
C           4.3578     2.058    2.118   0.072 
A*A         1.0723     2.265    0.473   0.650 
B*B        -5.0694     2.265   -2.238   0.060 
C*C         3.0083     2.265    1.328   0.226 
A*B         2.1214     2.688    0.789   0.456 
A*C         4.3198     2.688    1.607   0.152 
B*C         0.8786     2.688    0.327   0.753 
* The terms with P value less than or equal to 0.05 have been considered as significant. 
 
 
The regression equation (Equation 7.3) for efficiency was as follows, with a 
regression coefficient R
2
 of 83.04 %: 
 
                                                    23
865.7428.51ˆ xy                                     (7.3) 
 
The analysis designated that the only significant factor was feed rate for 
efficiency.  
The optimum conditions for the manufacturing of clarithromycin loaded 
microspheres by spray drying were determined as 168°C for inlet air temperature, 4.64 
ml/min for feed rate and 0.064 % (w/v) for clarithromycin concentration with 
desirability of 0.76. 
Statistical design for the production of cinnamon bark oil loaded microspheres 
was also carried out. Water activity, particle type and spray drying efficiency results 
were given in Table 7.8 according to run order of the design.  
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Table 7.8. Results of experiments performed according to statistical design for the 
production of cinnamon bark oil loaded microspheres. 
 
Run 
Number 
Inlet Air 
Temperature 
(A) 
Feed  
Rate 
(B) 
Cinnamon 
bark oil 
Concenration 
(C) 
Water 
Activity 
aw 
Particle 
Type 
Efficiency 
(%) 
1 -1 -1 -1 0.317 3 26.20 
2 1 -1 -1 0.326 3 36.85 
3 -1 1 -1 0.613 3 20.04 
4 1 1 -1 0.450 3 23.92 
5 -1 -1 1 0.414 3 18.63 
6 1 -1 1 0.325 4 16.60 
7 -1 1 1 0.902 4 5.83 
8 1 1 1 0.509 3 10.07 
9 -1.68 0 0 0.542 2 21.67 
10 1.68 0 0 0.409 3 14.79 
11 0 -1.68 0 0.350 2 18.99 
12 0 1.68 0 0.890 4 6.60 
13 0 0 -1.68 0.628 4 17.65 
14 0 0 1.68 0.391 4 5.33 
15 0 0 0 0.591 4 9.08 
16 0 0 0 0.585 4 9.41 
17 0 0 0 0.601 4 8.98 
 
 
The estimated regression coefficients for moisture content of cinnamon bark oil 
loaded microspheres were given in Table 7.9.  
 
Table 7.9. Estimated regression coefficients for water activity of cinnamon bark oil 
loaded microspheres 
 
Term       Coef   SE Coef T       P 
Constant    0.595525   0.05758   10.342   0.000 
A          -0.105866 0.04548   -2.328   0.053 
B           0.246314   0.04548  5.416   0.001 * 
C           0.005593   0.04548  0.123   0.906 
A*A        -0.147930  0.08418   -1.757   0.122 
B*B        -0.003430  0.08418   -0.041   0.969 
C*C        -0.113930  0.08418   -1.353   0.218 
A*B        -0.168291  0.09993   -1.684   0.136 
A*C        -0.115966  0.09993   -1.160   0.284 
B*C     0.089095   0.09993  0.892   0.402 
* The terms with P value less than or equal to 0.05 have been considered as significant. 
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The regression equation (Equation 7.4) for water activity was as follows, with a 
regression coefficient R
2
 of 86.30 %: 
 
                                                    21
246.0595.0ˆ xy                                       (7.4) 
 
The p-values verified the significance of the main factor of feed rate. 
Morphology of cinnamon bark oil loaded microspheres was also investigated by 
scanning electron microscopy. The particles were mostly wrinkled and the particle size 
was in the range of 1-5 μm. Particles were stickier than the clarithromycin loaded 
particles due to the insufficient drying. Low sphericity was observed (Figure 7.3). The 
micrographs depicted different particle shapes and sizes obtained at each run of central 
composite design for manufacturing of cinnamon bark oil loaded microspheres are 
shown in Figure A.2 in Appendix A. 
 
Run 
No 
5000x 10000x 
 
11 
  
 
Figure 7.3. SEM micrographs of cinnamon bark oil loaded microspheres manufactured 
by spray drying according to central composite design run numbers. 
 
 
The estimated regression coefficients for particle type of cinnamon bark oil 
loaded microspheres were given in Table 7.10.  
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Table 7.10. Estimated regression coefficients for particle type of cinnamon bark oil 
loaded microspheres 
 
Term           Coef   SE Coef T  P 
Constant    3.99137    0.3251   12.276   0.000 
A           0.20711    0.2568    0.807   0.446 
B           0.41421    0.2568    1.613   0.151 
C           0.24629    0.2568    0.959   0.369 
A*A        -1.41593    0.4753   -2.979   0.021 * 
B*B        -0.91593    0.4753   -1.927   0.095 
C*C         0.08407    0.4753    0.177   0.865 
A*B        -0.70711    0.5643   -1.253   0.250 
A*C         0.00000    0.5643    0.000   1.000 
B*C         0.00000    0.5643    0.000   1.000 
* The terms with P value less than or equal to 0.05 have been considered as significant. 
 
 
The regression equation (Equation 7.5) for particle type was as follows, with a 
regression coefficient R
2
 of 71.73 %: 
 
                                                    
2
12 416.1991.3ˆ xy                                            (7.5) 
 
This equation revealed that the main effect of pure quadratic term of inlet air 
temperature. 
 
Table 7.11. Estimated regression coefficients for efficiency of cinnamon bark oil loaded 
microspheres 
 
Term        Coef   SE Coef  T       P 
Constant    8.8148     3.141    2.807   0.026 
A           0.6398     2.480    0.258   0.804 
B          -7.2972     2.480   -2.942   0.022 * 
C          -9.4334     2.480   -3.803   0.007 * 
A*A        12.3947     4.591    2.700   0.031 * 
B*B         6.9639     4.591    1.517   0.173 
C*C         5.6580     4.591    1.232   0.258 
A*B        -0.1787     5.450   -0.033   0.975 
A*C        -4.3549     5.450   -0.799   0.451 
B*C        -0.0878     5.450   -0.016   0.988 
* The terms with P value less than or equal to 0.05 have been considered as significant. 
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The regression equation (Equation 7.6) for spray drying efficiency was as 
follows, with a regression coefficient R
2
 of 81.94 %: 
 
                                   
2
1322 395.12433.9297.7815.8ˆ xxxy                            (7.6) 
 
In the case of spray drying efficiency, coefficient estimates and the p-values 
verified the significance of the main factors of feed flow rate and cinnamon bark oil 
concentration. Inlet air temperature alone was not an effective parameter, but the pure 
quadratic term of inlet air temperature indicated significance.  
The optimum conditions for the manufacturing of cinnamon bark oil loaded 
microspheres by spray drying were determined as 181°C for inlet air temperature. 4.64 
ml/min for feed flow rate and 0.5 % (w/v) for clarithromycin concentration with 
desirability of 0.94. 
 
7.4. Characterization of Microspheres 
  
Particle Size and Surface Morphology 
 
The surface morphology of uncrosslinked and genipin crosslinked 
clarithromycin and cinnamon bark oil loaded chitosan microspheres produced under 
optimum spray drying conditions was observed by scanning electron microscopy 
studies and SEM pictures were given in Figure 7.4. Surface morphology was affected 
by the drug concentration and crosslinking. The sphericity of all microspheres 
synthesized was generally very high. Particle size was generally in the range of 1-5 µm. 
The surface of clarithromycin and cinnamon bark oil loaded microspheres was 
more wrinkled than that of control microspheres. This means that addition of 
clarithromycin or cinnamon bark oil decreaded the sphericity of the chitosan 
microspheres. Therefore, wrinkled structure was obtained.  Moreover, the particle size 
of clarithromycin and cinnamon bark oil loaded microspheres was smaller than the 
control microspheres. 
Particle size was significantly decreased by crosslinking due to the formation of 
more dense structure. Sphericity was very low in the case of genipin crosslinked 
cinnamon bark oil loaded microspheres. 
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(a) 
 
(b) 
 
Figure 7.4. SEM micrographs: (a). (b) control chitosan microspheres; (c). (d) cinnamon bark oil loaded microspheres; (e). (f) clarithromycin   
loaded microspheres; (g). (h) 5mM genipin crosslinked clarithromycin microspheres for 18h crosslinking; (i). (j) 5mM genipin 
crosslinked cinnamon bark oil microspheres for 18h crosslinking. 
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Zeta Potential 
 
 Zeta potential is representative of particle surface charge. Mucoadhesion is 
greatly dependent upon mucus and polymer structure including their charges. Chitosan 
is a cationic polysaccharide bearing primary amino and hydroxyl groups in each 
repeating unit. When protonated, primary amino groups carry a positive charge, which 
may facilitate electrostatic interactions with negatively charged mucin. When these 
amino groups are deprotonated, they can participate in hydrogen bonding with mucin 
along with the nonionic hydroxyl groups (Sogias et al., 2008). It was demonstrated that 
positive charge on the surface of chitosan could give rise to a strong electrostatic 
interaction with mucus or with a negatively charged mucosal surface (He et al., 2008; 
Dhawan et al., 2004). An insight into electrostatic interaction during mucoadhesion can 
be gained by measuring the zeta potential of chitosan microspheres. Table 7.12 shows 
the zeta potential values of clarithromycin, genipin and uncrosslinked/genipin 
crosslinked chitosan microspheres loaded with clarithromycin and cinnamon bark oil in 
phosphate buffer of pH 5. Our results showed that the zeta potential values of chitosan 
microspheres changed in the range of 21-30 mV.  
The zeta potential of the microspheres remained positive after the crosslinking 
with genipin, however, it decreased when increasing genipin concentration. This 
indicates that the positive charge of free amino groups at the microsphere surface 
decreased possibly by the electrostatic interaction between negatively charged genipin 
and positively charged free amino groups of chitosan. The positive zeta potential value 
of clarithromycin and cinnamon bark oil loaded microspheres is of great importance 
since positively charged microspheres can interact with negatively charged mucins 
(mucus glycoprotein), exhibiting mucoadhesive properties. 
 
 
 
 
 
 
 
 85 
Table 7.12. Zeta potentials of clarithromycin, genipin and uncrosslinked/genipin 
crosslinked chitosan microspheres loaded with clarithromycin and 
cinnamon bark oil 
 
Formulation 
Zeta potential 
(mV) 
clarithromycin -9.5 
genipin -12.4 
chitosan 32.5 
uncrosslinked chitosan-CLA microspheres 26.1 
chitosan-CLA- microspheres  
1mM genipin-1h crosslinked 
29.2 
chitosan-CLA- microspheres  
5mM genipin-1h crosslinked 
24.0 
chitosan-CLA- microspheres  
1mM genipin-18h crosslinked 
28.6 
chitosan-CLA- microspheres  
5mM genipin-18h crosslinked 
21.2 
uncrosslinked chitosan-cinnamon bark oil 
microspheres 
27.8 
chitosan-cinnamon bark oil- microspheres 
5mM genipin-1h crosslinked 
25.4 
chitosan-cinnamon bark oil- microspheres 
5mM genipin-18h crosslinked 
21.7 
 
 
Thermal Analysis 
 
Thermal properties of cinnamon bark oil was determined by DSC (Figure 7.5a) 
whereas thermal properties of clarithromycin, control microspheres, clarithromycin and 
cinnamon bark oil loaded microspheres were determined by TGA (Figure 7.5b-5e). 
TGA thermograms of control microspheres were shown in Figure 7.5d. Three 
decomposition steps were observed in thermograms. The first weight loss occurred in 
the range of 40-90°C, which can be attributed to free water and acetic acid evaporation. 
The second step occurred in the range of 110-175°C due to the evaporation of bound 
water. The third step, the main decomposition, occurred in the range of 250-290 °C 
with approximately 50% weight loss that should be due to the degradation of the 
polysaccharide chains and degradation of deacetylated units of chitosan. The weight 
loss occured in 3 steps even loading clarithromycin to the chitosan microspheres 
(Figure 7.5e. g and h). The free water and acetic acid evaporation occured at lower 
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temperature around 65°C in clarithromycin and cinnamon bark oil loaded microspheres 
than that of control microspheres as 72°C (Figure 7.5f). The evaporation of bound 
water was around 150°C in all cases. A little increase in the main decomposition 
temperature of clarithromycin and cinnamon bark oil loaded microspheres shows the 
higher stability of these microspheres compared to control microspheres. As a result, 
there was no significant difference in the thermal stabilities of the microspheres with 
the addition of essential oil or clarithromycin. 
 
 
(a) 
 
Figure 7.5. (a) Cinnamon bark oil DSC analysis; TGA thermograms of (b) 
clarithromycin; (c) genipin; (d) control chitosan microspheres; (e) 
clarithromycin loaded microspheres; (f) cinnamon bark oil loaded 
microspheres; (g) 1h genipin crosslinked clarithromycin loaded 
microspheres; (h) 18h genipin crosslinked clarithromycin loaded 
microspheres. 
 
 
 
 
 
 
 
 
 
(cont. on next page) 
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(b) 
 
 
(c) 
 
Figure 7.5. (cont.)     
 
               (cont. on next page) 
 
 88 
 
 
(d) 
 
 
(e) 
 
Figure 7.5. (cont.)     
 
 
               (cont. on next page) 
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(f) 
 
(g) 
Figure 7.5. (cont.)                   (cont. on next page) 
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(h) 
 
Figure 7.5. (cont.)       
 
 
The decomposition temperature of chitosan microspheres was 257.3 ºC (Figure 
7.6A), whereas that of the genipin crosslinked was 275 ºC (Figure 7.6B), which was 
between the decomposition temperatures of clarithromycin (at 309.1 ºC Figure 7.6C) 
and chitosan microspheres. Comparing the decomposition temperatures, it could be seen 
that the crosslinking of the polymer increased the stability of the microspheres with 
respect to the chitosan control microspheres.  
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Figure 7.6. TGA thermograms of (A) chitosan microspheres; (B) clarithromycin loaded 
chitosan microspheres and (C) clarithromycin. 
 
 
Effects of crosslinking and its time on the thermal stability of chitosan 
microspheres were investigated (Figure 7.7). It is evident that, stability of chitosan 
microspheres increased by increasing the crosslinking time. Because of the covalent 
bond between chitosan and genipin (i.e. amide (N-C=O) bonding), genipin crosslinked 
microspheres were considerably stable and had higher decomposition temperature 
(Figure 7.7A and B).  
 
 
 
Figure 7.7. TG curves of clarithromycin loaded genipin crosslinked chitosan 
microspheres (A) 18 hour; (B) 1h and (C) microspheres without genipin. 
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Nucleer Magnetic Resonans Spectrometry Analysis (
1
H-NMR) 
 
The structure of clarithromycin, control and clarithromycin loaded microspheres 
was investigated by 
1
H-NMR spectroscopy (Figure 7.8). In the range of 1.3-0.6 ppm, 
the characteristic signals of clarithromycin exist also in clarithromycin loaded chitosan 
microspheres meaning that clarithromycin was succesfully loaded into microspheres. 
However, the signal at 2.7 ppm belonging to (N-CH3) group of clarithromycin could 
not be observed in the spectrum of clarithromycin loaded microspheres. This may be 
due to the loss of desozamine sugar bound to C5 with β-glucosidic bond during the 
microsphere production. Clarithromycin is connected to the peptidil transferase zone in 
50S ribosomal unit of H. pylori by hydrogen bonding with the cladinose sugar 
connected to C3 with α-glicosidic bond of clarithromycin (Zuckerman, 2004; Gerrits et 
al., 2006). Since the cladinose sugar presents in clarithromycin loaded chitosan 
microspheres, the antimicrobial activity of clarithromycin in microspheres was 
maintained.  
 
 
Figure 7.8. 
1
H-NMR spectra: (a) control chitosan microspheres, (b) clarithromycin, (c) 
clarithromycin loaded microspheres. 
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Swelling and Degradation Properties of Microspheres 
 
The swelling and degradation properties of uncrosslinked/genipin crosslinked 
clarithromycin and cinnamon bark oil loaded microspheres in phosphate buffer of pH 5 
were examined by phase contrast microscope. After dropping buffer on microspheres, 
the photographs of microspheres were taken in specified time intervals. Swelling ratio 
was determined by the change of particle diameter with time. The photographs of 
clarithromycin and cinnamon bark oil loaded microspheres were given in Figure 7.9 
and Figure 7.10, respectively.  
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(a1) 
 
(a2) 
 
(b1) 
 
(b2) 
 
Figure 7.9. Phase contrast microscope photographs of clarithromycin loaded uncrosslinked (a1 and a2) and genipin crosslinked (b1 and b2) 
microspheres at t=0 min and t=120 min. 
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(b1) 
  
(b2) 
 
 
Figure 7.10. Phase contrast microscope photographs of cinnamon bark oil loaded uncrosslinked (a1 and a2) and genipin crosslinked (b1 and 
b2) microspheres at t=0 min and t=120 min. 
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Particle diameters of microspheres in all cases increased approximately 10% in 
buffer solution within 120 min. There was not a significant effect of genipin  
crosslinking on the swelling and degradation properties of microspheres. Particles 
remained stable for 120 min in buffer solution. 
 
7.5. Clarithromycin Stability in Different pH Solutions 
 
The stability of antibiotics in an acidic medium plays an important role in the 
eradication of H. pylori. In fact, lots of antibiotics have been reported with a strong in 
vitro H. pylori clearance effect but poor in vivo results. One reason for the failure is 
their instability in an acidic medium. It is crucial to maintain the stability of antibiotics 
during the prolongation of the gastric retarding time of a stomach-specific drug delivery 
system. As shown in Figure 7.11 and 7.12, the degradation profiles of clarithromycin in 
solutions at pHs 2.0. 3.0. 5.0 and 7.0 were determined. Furthermore the effect of pepsin 
addition to the gastric fluid on clarithromycin stability was investigated (Figure 7.11a 
and b).  
 
(a) 
 
(b) 
Figure 7.11. Stability of clarithromycin in simulated gastric fluid (pH 2.0) without 
pepsin (a); with pepsin (b). 
 
At pH 2.0, the clarithromycin degradation was much faster in SGF than that of 
pepsin incorporated SGF, and about 80 % of the drug degraded within 60 min. Zhu et 
al., 2006 investigated the pepsin mediated proteolysis of H.pylori and addition of pepsin 
alone or in gastric juice causes a marked increase in bacterial susceptibility, suggesting 
an important role for proteolysis in the killing of bacteria (Zhu et al., 2006). Together 
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with the proteolysis effect of pepsin on H. pylori and to increase the stability of 
clarithromycin in gastric pH, presence of pepsin would be beneficial in the eradication 
of the bacteria.  
 
 
 
 
 
Figure 7.12. Stability of clarithromycin in different pH medium. 
 
 
A different behavior was observed at pH‟s of 3.0 and 5.0. At pH 3.0 and 5.0, the 
clarithromycin degradation became slower, and about 15% of the drug degraded within 
180 min. At pH 7.0, the drug degradation was almost negligible in the considered time 
ranges and clarithromycin was particularly stable (Figure 7.12). 
From the data presented here it can be concluded that at gastric pH values of less 
than 2.0, which can readily occur in the stomach, clarithromycin will undergo rapid 
degradation. This is a factor which may significantly affect the antimicrobial activity of 
the drug since it lowers the drug concentrations at the target site to values below the 
MIC against H. pylori, leading to therapeutic failure (Erah et al., 1997). The use of 
proton-pump inhibitor is helpful for keeping the clarithromycin stability by increasing 
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the gastric pH. Incorporation of the drug into microspheres which yields the controlled 
release may be another way in maintaing the clarithromycin stability. 
 
7.6. Release of Clarithromycin and Cinnamon Bark Oil from 
Microspheres  
 
The in vitro release of clarithromycin and cinnamon bark oil from microspheres 
was performed at 37°C and 150 rpm in a thermoshaker in phosphate buffer (pH 5). 250 
l release medium was withdrawn at predetermined time intervals and equivalent fresh 
medium was replaced. Collected samples were then analyzed for drug content 
(claritromisin and cinnamon bark oil). The clarithromycin and cinnamon bark oil 
amounts in release medium were obtained from the calibration curves given in Figure 
7.13 and 7.14. respectively. The clarithromycin amount in release medium was 
determined by HPLC method as explained in experimental section. 
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Figure 7.13. Calibration curve for clarithromycin. 
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Figure 7.14. Calibration curve for cinnamon bark oil. 
 
 
The clarithromycin amount in release medium was determined by HPLC 
method.  
As shown in Figure 7.15, in vitro release of clarithromycin from the chitosan 
microspheres was evaluated under various conditions. As known, many parameters can 
affect the drug release behavior of chitosan microspheres. These parameters include 
chitosan concentration, crosslinker concentration, drug/polymer ratio, temperature, 
release medium, etc. In this study, at constant drug/polymer ratio, the effects of 
crosslinking concentration and its time on the drug release behavior were investigated. 
As stated in previous section, clarithromycin was confirmed to be stable for the 
considered time range of the release study at 37 ºC at pH 5.0 (Figure 7.12). The 
cumulative release of clarithromycin from chitosan microspheres showed a burst effect. 
In order to obtain prolonged release of clarithromycin from the microspheres, genipin 
was used as a crosslinking agent. Genipin addition significantly affected the release 
profile of the drug as shown in Figure 7.16. Clarithromycin release from crosslinked 
chitosan microspheres was characterized in two steps as an initial rapid release of drug 
(burst effect) followed by slow release. In general 45-55% of drug was released from 
microspheres within first few minutes (Figure 7.15). Most probably the drug was 
located at the surface of the microspheres during the particle formation, which resulted 
in the burst effect. It is evident that controlled slow release profile was observed 
thereafter (Figure 7.15).  
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Figure 7.15. Clarithromycin release from chitosan microspheres to phosphate buffer of 
pH 5.0. 
 
 
The effect of crosslinker concentration on the release profile was investigated by 
changing the genipin concentration from 1 mM to 5 mM by keeping crosslinking time 
constant as 1 hour. As the genipin concentration of the prepared microspheres 
increased, the release rate increased while extent of drug release decreased significantly. 
This could be attributed to increase in chitosan matrix density (because of the higher 
crosslinking profile), decrease in free volume and increase in diffusion path length 
which the drug molecules have to traverse.  
In vitro release data were applied to various kinetics models; zero order 
(Equation 5.14), first order (Equation 5.13). Higuchi_square root of time analysis 
(Equation 5.9) to predict the drug release mechanism from the microspheres. The 
release kinetics of clarithromycin were analyzed by Ficks Law and applying square root 
of time analysis, which were shown in Figures 7.16 and 7.17.  
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Figure 7.16. Fractional release of clarithromycin loaded microspheres crosslinked with 
1 mM genipin for 1h. 
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Figure 7.17. Fractional release of clarithromycin loaded microspheres crosslinked with 
5 mM genipin for 1h. 
 
 
According to linear patterns of both plots and the relevant R
2
 values, square root 
time kinetic analysis suggested that release from microspheres was initially governed 
by drug dissolution and followingly diffusion through the swollen matrix. The slopes of 
the first linear portion of the plots indicated that about 75% of the drug was released 
within few minutes. This behaviour is important for the therapeutic activity of the 
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clarithromycin. Initial dose can be instanteneously achieved by administrating the 
microspheres. It is expected to achieve prolonged release of clarithromycin thereafter. 
Thus, second linear part in Figures 7.16 and 7.17 suggest that the controlled release of 
clarithromycin from genipin crosslinked chitosan microspheres.  
It is important to notice that release rate decreased by increasing the genipin 
concentration, which is probably due to the higher crosslinking ratio of chitosan and 
accordingly higher resistance to clarithromycin to diffuse. The mucoadhesive property 
of chitosan is also very beneficial since after mucoadhesion of chitosan microspheres to 
the gastric surface, controlled release of clarithromycin will be continued. The drug 
dose was enough to achieve minimum inhibitory concentration to eradicate the H. 
pylori, 3.94 mg of clarithromycin remained in 50 mg of microspheres after dissolution 
of the clarithromycin, probably found in the outer surface of the microspheres. 
Minimum inhibitory concentration of the clarithromycin on the H. pylori was found as 
0.125 μg/ml. The required MIC value is effectively achieved by encapsulated 
clarithromycin dose. The local delivery because of the mucoadhesive property of the 
chitosan will also be very beneficial to achieve MIC of clarithromycin at infected area. 
The effect of crosslinking time on the release kinetic was also investigated by 
changing crosslinking time from 1hour to 18 hour. Crosslinking time directly affects 
the release profile of the clarithromycin (Figure 7.18). 
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Figure 7.18. Effect of crosslinking time on the release profile of clarithromycin. 
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Increasing the crosslinking time yielded in burst effect. Square root of time 
kinetic analysis in Figure 7.19 indicates that about 90-95 % of the clarithromycin was 
released within few minutes.  
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Figure 7.19. Square root of time analysis of clarithromycin release from clarithromycin 
loaded microspheres crosslinked with 5 mM genipin for 18h. 
 
This inverse effect is due to the decrease in the free amino groups on chitosan 
surface, which also have role in drug-chitosan interaction. Electrostatic interactions 
between the negative surface charge of the clarithromycin (Bele et al., 2005), and the 
number of available positive chitosan charges could be the reason of prolonged release 
when the genipin crosslinking time is lower. This interaction resists clarithromycin to 
diffuse rapidly and decrease the diffusion rate. However, increasing the crosslinking 
time should decrease the positive charge on chitosan surface and accordingly to increase 
the diffusion rate. 
Release profiles of cinnamon bark oil from chitosan microspheres are shown in 
Figure 7.20. The effect of crosslinking on the release profile is also included. 5 mM of 
genipin was used for crosslinking and the effect of crosslinking time was investigated 
by changing time from 1 h to 18h. 
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Figure 7.20. Cinnamon bark oil release profile from chitosan microspheres and effects 
of genipin and crosslinking time on release profile. 
 
Rapid release of cinnamon oil was seen at the initial period of the release 
profiles. About 60% of cinnamon oil was released at that period for uncrosslinked 
microspheres. Interestingly, controlled release of the oil was achieved thereafter. 
Eugenol and trans-cinnamaldehyde are two very important terpenoids found in 
cinnamon oil, having –methoxy and =O groups, respectively, which are responsible in 
chemical reaction with the chitosan‟s amino groups. Similarly, genipin has active 
methoxy group, which reacts with chitosan for crosslinking. So, slow release profile of 
cinnamon oil from uncrosslinked chitosan microspheres can probably be explained by 
the chemical interaction.  
Square root of time kinetic analysis in Figure 7.21 also indicates the controlled 
release profile of cinnamon oil from chitosan microspheres. Similarly, two linear 
sections were obtained; in the first linear section for burst release (at the initial period of 
release), and the other one for controlled release. The linearity of the line correponds to 
the diffusion controlled release of cinnamon oil.  
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Figure 7.21. Square root of time analysis of cinnamon bark oil release from cinnamon 
bark oil loaded chitosan microspheres without crosslinking with genipin. 
 
It significantly affected by the addition of 5 mM genipin as crosslinking agent. 
and about 45% of cinnamon oil was released within the initial period. Moreover, 
crosslinking time directly affected the rate of the cinnamon oil release at the second 
linear section (Figures 7.22 and 7.23). Release rate decreased by increasing the 
crosslinking time from 1h to 18h. However, slowest release profile was achieved in the 
case of the genipin free cinnamon oil-chitosan microspheres. This may probably 
because of the competition between the active groups of genipin and of cinnamon oil 
active compounds‟ (e.g. trans-cinnamaldehyde, eugenol etc.) for amino groups of 
chitosan.  
 
 
Figure 7.22. Square root of time analysis of cinnamon bark oil release from cinnamon 
bark oil loaded microspheres crosslinked with 5 mM genipin for 1h. 
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Figure 7.23. Square root of time analysis of cinnamon bark oil release from cinnamon 
bark oil loaded microspheres crosslinked with 5 mM genipin for 18h. 
 
 The effective diffusivities (Dc) were calculated via the long term [ 7.0
M
M t ] 
solution of Crank Equation (Equation 5.7) and given in Appendix B (Table B.1). In 
clarithromycin loaded microspheres genipin crosslinking time did not affect the 
diffusivity significantly. However, increasing crosslinker concentration decreased the 
diffusivity due to the increase in chitosan matrix density and decrease in free volume. In 
cinnamon bark oil loaded microspheres, crosslinking did not change the diffusivity 
significantly. 
 
7.7. The Effects of Clarithromycin and Cinnamon Bark Oil Released 
from Microspheres on H. pylori  
 
Serial dilutions of samples taken at 0, 8, 24, 32 and 48 h of incubation from the 
control microsphere suspensions were cultivated in 7% horse blood supplemented 
Columbia Blood Agar in an anaerobic jar (Oxoid) containing GasPak Campy Container 
System (Becton Dickinson and Company) at 37°C in a microaerophilic environment for 
3 days. At the end of three days, there was H. pylori growth in each dilution plates.  
Viable colony counts in antimicrobial activity test of clarithromycin and 
cinnamon bark oil released from microspheres were given in Table 7.13. It was proved 
before the inhibition tests that H. pylori can grow in liquid growth medium (5% FBS 
incorporated Brucella Broth) for four days. In the case of incorporating the control 
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chitosan microspheres into the growth medium, H. pylori was able to grow in the 
presence of control microspheres. This means that control microspheres did not inhibit 
the H. pylori growth. 
 
Table 7.13. Viable colony counts in antimicrobial activity test of clarithromycin and 
cinnamon bark oil released from microspheres 
 
Microsphere 
Viable Colony Count, CFU x10
9
 
t=0h t=8h t=24h t=32h t=48h 
chitosan (control) microspheres 62 115 138 162 168 
uncrosslinked chitosan-
clarithromycin microspheres 
89 0 0 0 0 
uncrosslinked chitosan-cinnamon 
bark oil microspheres 
40 0 0 0 0 
genipin crosslinked chitosan-
clarithromycin microspheres 
77 0 0 0 0 
 
 
In the case of incorporation of the clarithromycin loaded chitosan microspheres 
into the growth medium, although there was a growth in the samples of t=0 hour, no 
growth was observed in the samples of t=8, t=24, t=32 and t=48 hours. This result 
indicated that clarithromycin released from the microspheres had an antimicrobial 
activity and inhibited the H. pylori growth. Similarly, except the sample of t=0 hour, 
there was not any growth in the t=8, t=24, t=32 and t=48 hours samples taken from the 
cinnamon bark oil loaded microspheres suspended growth medium. Thus, it can be said 
that cinnamon bark oil released from the microspheres also inhibited the growth of H. 
pylori. 
 The effects of clarithromycin and cinnamon bark oil released from genipin 
crosslinked microspheres were also tested on H. pylori in a similar way. In both cases, 
there was not any growth in the t=8, t=24, t=32 and t=48 hours samples taken from the 
growth medium which means that crosslinking by genipin did not affect the 
antibacterial activity of clarithromycin and cinnamon bark oil. 
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CHAPTER 8 
 
CONCLUSIONS 
 
Helicobacter pylori is one of the most common pathogens, colonising an 
estimated half of all humans. It is associated with the development of serious 
gastroduodenal diseases including peptic ulcers, gastric lymphoma and chronic gastritis. 
Current recommended regimes are not wholly effective due to poor permeability of the 
antibiotics across the mucus layer, poor stability of the drug in the acidic pH of the 
stomach, side effects, bacterial resistance and antibiotic allergy of some people. Gastric 
mucoadhesive delivery systems potentially allow increased penetration of the mucus 
layer and therefore increased drug concentration at the site of action. Incorporating 
antibiotic into the chitosan microspheres has a potential to overcome these difficulties. 
To eradicate the antibiotic-resistant strains and prevent reinfection the development of 
new drug delivery systems carrying biologically active compounds from plants and 
other natural sources are considerably attractive. 
The objective of this study was to produce clarithromycin and cinnamon bark oil 
loaded microspheres to achieve controlled release. Among five essential oils cinnamon 
bark oil, having MIC of 8 µg/ml, showed the strongest anti-H. pylori activity. MIC 
value is important to adjust the suitable drug formulations and dosage. The significance 
of inlet air temperature, drug concentration and feed flow rate on spray drying 
efficiency and properties of clarithromycin and cinnamon bark oil loaded microspheres 
and the optimum spray drying conditions were analyzed by Central Composite Design 
(CCD) and Response Surface Methodology (RSM). The optimum conditions for the 
manufacturing of clarithromycin and cinnamon bark oil loaded microspheres by spray 
drying were determined as 168°C and 181°C for inlet air temperature, 4.64 ml/min for 
feed rate and 0.064 % and 0.5 % (w/v) for drug concentration with desirability of 0.76 
and 0.94, respectively. Uncrosslinked and genipin crosslinked clarithromycin and 
cinnamon bark oil loaded chitosan microspheres to be used in release studies were 
produced by spray drying according to the optimum conditions. The use of natural 
crosslinker, genipin, to achieve controlled release has been important because of its 
markedly lower cytotoxicity as compared with alternative crosslinker, glutaraldehyde.  
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Resulting microspheres were wrinkled and spherical with size of 1-5µm. The 
positive zeta potentials of microspheres showed the potential electrostatic interaction 
between the negatively charged mucus and microspheres.Crosslinker concentration and 
crosslinking time were changed to evaluate their effects on release kinetics. 
Clarithromycin and cinnamon bark oil release from microspheres were performed in 
phosphate buffer of pH 5. Kinetic models were used to determine the release 
mechanism. Release from microspheres was diffusion controlled following the 
instantaneous burst effect. Higuchi equation (square root of time analysis) described the 
release characteristic. As the genipin concentration increased, clarithromycin release 
rate decreased whereas extent of release increased. However, slowest cinnamon bark oil 
release rate was achieved in the case of the genipin free (uncrosslinked) chitosan 
microspheres. This may probably because of the competition between the active groups 
of genipin and cinnamon bark oil for amino groups of chitosan. There is not any distinct 
evidence of chemical crosslinking according to the experiments and characterization 
studies performed. In release tests, cinnamon bark oil and clarithromycin released from 
the microspheres inhibited the growth of H. pylori resulting that the antibacterial 
activity of cinnamon bark oil and clarithromycin was maintained during the 
microsphere manufacturing. 
This dissertation describes a novel approach that is based on the development of 
chitosan microspheres for controlled release of essential oil besides clarithromycin to 
eradicate Helicobacter pylori. This work has demonstrated the potential of chitosan 
based microspheres as mucoadhesive drug carrier system for the controlled release of 
clarithromycin and cinnamon bark oil in the treatment of H. pylori infection.  
In further studies, the effects of polymer/drug ratio and genipin crosslinking of 
chitosan microspheres should be investigated in more detailed for sustained drug 
release. Moreover, the mucoadhesion tests are required to evaluate the mucoeadhesion 
strength of resultant microspheres due to the particular importance of stomach specific 
drug release. Additionally, researches on the investigation of in vivo product stability 
and tissue response and the impact on bioavailability and release rates using appropriate 
animal models should be initiated. 
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APPENDIX A 
 
SEM MICROGRAPHS OF MICROSPHERES IN OPTIMIZATION STUDY 
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Figure A.1. SEM micrographs of clarithromycin loaded microspheres manufactured by spray drying according to central composite design run 
numbers. 
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Figure A.2. SEM micrographs of cinnamon bark oil loaded microspheres manufactured by spray drying according to central composite design 
run numbers. 
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APPENDIX B 
 
DETERMINATION OF EFFECTIVE DIFFUSION COEFFICIENTS 
 
The effective diffusivities (Dc) were calculated via the long term [ 7.0
M
M t ] 
solution of Crank Equation (Equation 5.7) and given in Appendix B. By taking Ln of 
both sides; 
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Rearranging the Equation A.1; 
 
                                    t
R
D
xLn
M
M
Ln
p
ct















 















2
2
2
6
1   (B.2) 
 
The plot between the Ln (1-Mt/M∞) versus t is plotted and Dc is found from the 
slope of the plot. 
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Table B.1. The plots used to calculate (Dp) 
 
Sample 
code # 
Mt/M∞  versus time plot Ln(1- mt/m∞) versus t plot for mt/m∞>0.7 
1 
0
0.2
0.4
0.6
0.8
1
1.2
0 10 20 30 40
time (min)
M
t/M
∞
 
Burst effect 
2 
0
0.2
0.4
0.6
0.8
1
1.2
0 10 20 30 40
time (min)
M
t/M
∞
 
y = -0.0663x - 0.69
R2 = 0.9552
-2
-1.5
-1
-0.5
0
0 5 10 15 20
time (min)
L
n
(1
-M
t/
M
s
)
 
3 
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0.2
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0 50 100 150
time (min)
M
t/M
∞
 
y = -0.0159x - 1.5873
R
2
 = 0.9981
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0 50 100 150
time (min)
L
n
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t/
M
s
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0 100 200 300
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M
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y = -0.0702x - 3.0049
R
2
 = 0.945
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0 2 4 6
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L
n
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-M
t/
M
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Table B.1. (cont.) 
 
5 
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y = -0.0178x - 3.1675
R
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Table B.2. Effective Diffusion Coefficients 
 
Sample Code and name Dc (*10
14
) 
(m
2
/s) 
#1. Clarithromycin loaded chitosan microspheres; without genipin. ----- 
#2. 1mM genipin crosslinked clarithromycin loaded microspheres; 1h. 12.2 
#3. 5mM genipin crosslinked clarithromycin loaded microspheres; 1h. 2.92 
#4. 1mM genipin crosslinked clarithromycin loaded microspheres; 18h. 12.9 
#5. 5mM genipin crosslinked clarithromycin loaded microspheres; 18h. 3.27 
#6. Cinnamon bark oil loaded chitosan microspheres. with 5mM genipin.1h. 5.1 
#7. Cinnamon bark oil loaded chitosan microspheres. with 5mM genipin.18h. 4.4 
#8. Cinnamon bark oil loaded chitosan microspheres. without genipin. 5.1 
 
 
 149 
VITA 
 
DUYGU ALTIOK 
 
Date of Birth : 01.04.1978 
Place of Birth : Manisa/Turkey 
Citizenship : Turkish 
 
EDUCATION 
[1996-2000] B.Sc. (Food Engineering) 
Middle East Technical University 
Department of Food Engineering, Ankara, Turkey 
 
[2001-2004] M.Sc. (Food Engineering) 
Izmir Institute of Technology 
Department of Food Engineering, Ġzmir, Turkey 
Dissertation: Kinetic Modelling of Lactic Acid Production from Whey. 
Advisor: Prof. Dr. ġebnem HARSA 
Co-advisor: Assoc. Prof. Dr. Figen TOKATLI 
 
[2004-2011] Ph.D. (Chemical Engineering) 
Izmir Institute of Technology 
Department of Chemical Engineering, Ġzmir, Turkey 
Dissertation: Preparation and Evaluation of Chitosan Microspheres for Eradication of 
Helicobacter Pylori. 
Advisor: Prof. Dr. Funda TIHMINLIOĞLU 
 
ACADEMIC POSITIONS HELD 
Research Assistant Izmir Institute of Technologyi Faculty of Engineering, Department 
of Chemical Engineering (September 2004-July 2011). 
Research Assistant Izmir Institute of Technologyi Faculty of Engineering, Department 
of Food Engineering (October 2001-September 2004). 
 
PUBLICATIONS 
ALTIOK, D.; Altıok, E.; Tıhmınlıoğlu, F. Physical, antibacterial and antioxidant 
properties of chitosan films incorporated with thyme oil for potential wound 
healing applications, 2010, Journal of Materials Science: Materials in Medicine, 
21, 2227-2236. 
ALTIOK, D.; Basal, G.; Bayraktar, O. Antibacterial Properties of Silk Fibroin/Chitosan 
Blend Films Loaded with Plant Extract, 2010, Fibers and Polymers, 11, 21-27. 
ALTIOK, D.; Gürbüz, E.D.; Bekmen, N.; Tıhmınlıoğlu, F.; Yılmaz, Ö. Antimicrobial 
Activity of Essential Oils Against H. Pylori, 2010, Helicobacter, 15: 4, 335-336. 
ALTIOK, D.; Gürbüz, E.D.; Bekmen, N.; Tıhmınlıoğlu, F.; Yılmaz, Ö. A Natural 
Antioxidant: Trans-resveratrol Against H. Pylori, 2010, Helicobacter, 15: 4, 334-
335. 
ALTIOK, D.; Tokatlı, F.; Harsa, S. Kinetic modelling of lactic acid production from 
whey by Lactobacillus casei (NRRL B-441), 2006, Journal of Chemical 
Technology and Biotechnology, 81, 190-1197.  
